Patent Application
20210403435
The present invention relates to herbicidally active pyridazine derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions for controlling undesirable plant growth: in particular the use for controlling weeds, in crops of useful plants.
The natural product pyridazomycin is an example of a pyridazine derivative and was first disclosed as a new antifungal antibiotic in The Journal Of Antibiotics, 1988, 41(5), 595-601. Further pyridazine derivatives of pyridazomycin have been disclosed and tested for their antimicrobial activity, see Arch. Pharm. 1995, 328(4), 307-312 and Pharmazie 1996, 51(2), 76-83.
The present invention is based on the finding that pyridazine derivatives of formula (I) as defined herein, exhibit surprisingly good herbicidal activity. Thus, according to the present invention there is provided the use of a compound of formula (I) or an agronomically acceptable salt or zwitterionic species thereof, as a herbicide:
wherein
R1 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, C1-C6haloalkyl, —OR7, —OR15a, —N(R6)S(O)2R15, —N(R6)C(O)R15, —N(R6)C(O)OR15, —N(R6)C(O)NR16R17, —N(R6)CHO, —N(R7a)2 and —S(O)rR15;
R2 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl and C1-C6haloalkyl;
and wherein when R1 is selected from the group consisting of —OR7, —OR15a, —N(R6)S(O)2R15, —N(R6)C(O)R15, —N(R6)C(O)OR15, —N(R6)C(O)NR16R17, —N(R6)CHO, —N(R7a)2 and —S(O)R15, R2 is selected from the group consisting of hydrogen and C1-C6alkyl; or
R1 and R2 together with the carbon atom to which they are attached form a C3-C6cycloalkyl ring or a 3- to 6-membered heterocyclyl, which comprises 1 or 2 heteroatoms individually selected from N and O; and
Q is (CR1aR2b)m;
m is 0, 1, 2 or 3;
each R1a and R2b are independently selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, —OH, —OR7, —OR15a, —NH2, —NHR15a, —N(R6)CHO, —NR7bR7c and —S(O)rR15; or each R1a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl ring or a 3- to 6-membered heterocyclyl, which comprises 1 or 2 heteroatoms individually selected from N and O; and
R3, R4 and R5 are independently selected from the group consisting of hydrogen, cyano, nitro, C1-C6alkyl, C1-C6thioalkyl, C1-C6fluoroalkyl, C1-C6fluoroalkoxy, C1-C6alkoxy, C3-C6cycloalkyl, phenyl and —N(R6)2;
each R6 is independently selected from hydrogen and C1-C6alkyl;
each R7 is independently selected from the group consisting of C1-C6alkyl, —S(O)2R15, —C(O)R15, —C(O)OR15 and —C(O)NR16R17;
each R7a is independently selected from the group consisting of —S(O)2R15, —C(O)R15, —C(O)OR15, —C(O)NR16R17 and —C(O)NR6R15a;
R7b and R7c are independently selected from the group consisting of C1-C6alkyl, —S(O)2R15, —C(O)R15, —C(O)OR15, —C(O)NR16R17 and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different; or
R7b and R7c together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl ring which optionally comprises one additional heteroatom individually selected from N, O and S; and
R8a is selected from the group consisting of hydrogen, —OH, —OR7, —S(O)rR15, —C(O)OR10, —C(O)R15, —C(O)NR16R17, —S(O)2NR16R17, —NR7dR7e, R15S(O)rC1-C3alkyl-, R16R17NS(O)2C1-C3alkyl-, R15C(O)C1-C3alkyl-, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6cycloalkoxy, C3-C6cycloalkylC1-C3alkyl-, C3-C6cycloalkylC1-C3alkoxy-, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, cyanoC1-C6alkyl-, C1-C3alkoxyC1-C3alkoxy-, C1-C6haloalkoxy, C1-C3haloalkoxyC1-C3alkyl-, C3-C6alkenyloxy, C3-C6alkynyloxy, —C(R6)═NOR6, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S(O)r, heteroaryl and heteroarylC1-C2alkyl-, wherein the heteroaryl is a 5- or 6-membered aromatic ring, which comprises 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and wherein said C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, heteroaryl or heteroarylC1-C2alkyl-, are optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different;
R8b is selected from the group consisting of hydrogen, —OR7, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6halocycloalkyl, C3-C6cycloalkoxy, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, C1-C3alkoxyC1-C3alkoxy-, C1-C6haloalkoxy, C1-C3haloalkoxyC1-C3alkyl-, C3-C6alkenyloxy and C3-C6alkynyloxy; or
R8a and R8b together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl, which optionally comprises 1 or 2 additional heteroatoms independently selected from N, O and S(O)r, and wherein said heterocyclyl moiety is optionally substituted by 1 or 2 R9 substituents, which may be the same or different; and
R7d and R7e are independently selected from the group consisting of hydrogen, C1-C6alkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, C1-C3alkoxyC1-C3alkyl-, C2-C6alkynyl, —S(O)2R15, —C(O)R15, —C(O)OR15, —C(O)NR16R17 and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents;
each R9 is independently selected from the group consisting of —OH, halogen, cyano, —N(R6)2, C4alkyl, C1-C4alkoxy, C1-C4haloalkyl and C1-C4haloalkoxy;
X is selected from the group consisting of C3-C6cycloalkyl, phenyl, a 5- or 6-membered heteroaryl, which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S, and a 4- to 6-membered heterocyclyl, which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S, and wherein said cycloalkyl, phenyl, heteroaryl or heterocyclyl moieties are optionally substituted by 1 or 2 R9 substituents, and wherein the aforementioned CR1R2, Q and Z moieties may be attached at any position of said cycloalkyl, phenyl, heteroaryl or heterocyclyl moieties;
n is 0 or 1;
Z is selected from the group consisting of —C(O)OR10, —CH2OH, —CHO, —C(O)NHOR11, —C(O)NHCN, —OC(O)NHOR11, —OC(O)NHCN, —NR6C(O)NHOR11, —NR6C(O)NHCN, —C(O)NHS(O)2R12, —OC(O)NHS(O)2R12, —NR6C(O)NHS(O)2R12, —S(O)2OR10, —OS(O)2OR10, —NR6S(O)2OR10, —NR6S(O)OR10, —NHS(O)2R14, —S(O)OR10, —OS(O)OR10, —S(O)2NHCN, —S(O)2NHC(O)R18, —S(O)2NHS(O)2R12, —OS(O)2NHCN, —OS(O)2NHS(O)2R12, —OS(O)2NHC(O)R18, —NR6S(O)2NHCN, —NR6S(O)2NHC(O)R18, —N(OH)C(O)R15, —ONHC(O)R15, —NR6S(O)2NHS(O)2R12, —P(O)(R13)(OR10), —P(O)H(OR10), —OP(O)(R13)(OR10), —NR6P(O)(R13)(OR10) and tetrazole;
R10 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl and benzyl, and wherein said phenyl or benzyl are optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different;
R11 is selected from the group consisting of hydrogen, C1-C6alkyl and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different;
R12 is selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, —OH, —N(R6)2 and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different;
R13 is selected from the group consisting of —OH, C1-C6alkyl, C1-C6alkoxy and phenyl;
R14 is C1-C6haloalkyl;
R15 is selected from the group consisting of C1-C6alkyl and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different;
R15a is phenyl, wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different;
R16 and R17 are independently selected from the group consisting of hydrogen and C1-C6alkyl; or R16 and R17 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl ring which optionally comprises one additional heteroatom independently selected from N, O and S; and
R18 is selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, —N(R6)2 and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different;
and
r is 0, 1 or 2.
Certain compounds of formula (I) are known:
Thus in a second aspect of the invention there is provided a compound of formula (I) that are not i) (5-(4-carbamoylpyridazin-1-ium-1-yl)pentanoic acid), ii) (2-amino-4-(4-carbamoylpyridazin-1-ium-1-yl)butanoic acid), or iii) (2-amino-5-(4-carbamoylpyridazin-1-ium-1-yl)pentanoic acid) listed above.
According to a third aspect of the invention there is provided an agrochemical composition comprising a herbicidally effective amount of a compound of formula (I) and an agrochemically-acceptable diluent or carrier. Such an agricultural composition may further comprise at least one additional active ingredient.
According to a fourth aspect of the invention, there is provided a method of controlling or preventing undesirable plant growth, wherein a herbicidally effective amount of a compound of formula (I), or a composition comprising this compound as active ingredient, is applied to the plants, to parts thereof or the locus thereof.
As used herein, the term “halogen” or “halo” refers to fluorine (fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo), preferably fluorine, chlorine or bromine.
As used herein, cyano means a —CN group.
As used herein, hydroxy means an —OH group.
As used herein, nitro means an —NO2 group.
As used herein, the term “C1-C6alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to six carbon atoms, and which is attached to the rest of the molecule by a single bond. C1-C4alkyl and C1-C2alkyl are to be construed accordingly. Examples of C1-C6alkyl include, but are not limited to, methyl (Me), ethyl (Et), n-propyl, 1-methylethyl (iso-propyl), n-butyl, and 1-dimethylethyl (t-butyl or tBu).
As used herein, the term “C1-C6alkoxy” refers to a radical of the formula —ORa where Ra is a C1-C6alkyl radical as generally defined above. C1-C4alkoxy is to be construed accordingly. Examples of C1-4 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, iso-propoxy and t-butoxy.
As used herein, the term “C1-C6haloalkyl” refers to a C1-C6alkyl radical as generally defined above substituted by one or more of the same or different halogen atoms. C1-C4haloalkyl is to be construed accordingly. Examples of C1-C6haloalkyl include, but are not limited to chloromethyl, fluoromethyl, fluoroethyl, difluoromethyl, trifluoromethyl and 2,2,2-trifluoroethyl.
As used herein, the term “C2-C6alkenyl” refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond that can be of either the (E)- or (Z)-configuration, having from two to six carbon atoms, which is attached to the rest of the molecule by a single bond. C2-C4alkenyl is to be construed accordingly. Examples of C2_C6alkenyl include, but are not limited to, prop-1-enyl, allyl (prop-2-enyl) and but-1-enyl.
As used herein, the term “C2-C6haloalkenyl” refers to a C2-C6alkenyl radical as generally defined above substituted by one or more of the same or different halogen atoms. Examples of C2-C6haloalkenyl include, but are not limited to chloroethylene, fluoroethylene, 1,1-difluoroethylene, 1,1-dichloroethylene and 1,1,2-trichloroethylene.
As used herein, the term “C2-C6alkynyl” refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to six carbon atoms, and which is attached to the rest of the molecule by a single bond. C2-C4alkynyl is to be construed accordingly. Examples of C2-C6alkynyl include, but are not limited to, prop-1-ynyl, propargyl (prop-2-ynyl) and but-1-ynyl.
As used herein, the term “C1-C6haloalkoxy” refers to a C1-C6alkoxy group as defined above substituted by one or more of the same or different halogen atoms. C1-C4haloalkoxy is to be construed accordingly. Examples of C1-C6haloalkoxy include, but are not limited to, fluoromethoxy, difluoromethoxy, fluoroethoxy, trifluoromethoxy and trifluoroethoxy.
As used herein, the term “C1-C3haloalkoxyC1-C3alkyl” refers to a radical of the formula Rb—O—Ra— where Rb is a C1-C3haloalkyl radical as generally defined above, and Ra is a C1-C3alkylene radical as generally defined above.
As used herein, the term “C1-C3alkoxyC1-C3alkyl” refers to a radical of the formula Rb—O—Ra— where Rb is a C1-C3alkyl radical as generally defined above, and Ra is a C1-C3alkylene radical as generally defined above.
As used herein, the term “C1-C3alkoxyC1-C3alkoxy-” refers to a radical of the formula Rb—O—Ra—O— where Rb is a C1-C3alkyl radical as generally defined above, and Ra is a C1-C3alkylene radical as generally defined above.
As used herein, the term “C3-C6alkenyloxy” refers to a radical of the formula —ORa where Ra is a C3-C6alkenyl radical as generally defined above.
As used herein, the term “C3-C6alkynyloxy” refers to a radical of the formula —ORa where Ra is a C3-C6alkynyl radical as generally defined above.
As used herein, the term “hydroxyC1-C6alkyl” refers to a C1-C6alkyl radical as generally defined above substituted by one or more hydroxy groups.
As used herein, the term “cyanoC1-C6alkyl” refers to a C1-C6alkyl radical as generally defined above substituted by one or more cyano groups.
As used herein, the term “C3-C6cycloalkyl” refers to a stable, monocyclic ring radical which is saturated or partially unsaturated and contains 3 to 6 carbon atoms. C3-C4cycloalkyl is to be construed accordingly. Examples of C3-C6cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
As used herein, the term “C3-C6halocycloalkyl” refers to a C3-C6cycloalkyl radical as generally defined above substituted by one or more of the same or different halogen atoms. C3-C4halocycloalkyl is to be construed accordingly.
As used herein, the term “C3-C6cycloalkoxy” refers to a radical of the formula —ORa where Ra is a C3-C6cycloalkyl radical as generally defined above.
As used herein, the term “C3-C6cycloalkylC1-C3alkyl-” refers to a C3-C6cycloalkyl ring as defined above attached to the rest of the molecule by a C1-C3alkylene radical as defined above. Examples of C3-C6cycloalkylC1-C3alkyl- include, but are not limited to cyclopropyl-methyl- and cyclobutyl-ethyl-.
As used herein, the term “C3-C6cycloalkylC1-C3alkoxy-” refers to a C3-C6cycloalkyl ring as defined above attached to the rest of the molecule by a C1-C3alkoxy radical as defined above. Examples of C3-C6cycloalkylC1-C3alkoxy- include, but are not limited to cyclopropylmethoxy-.
As used herein, except where explicitly stated otherwise, the term “heteroaryl” refers to a 5- or 6-membered monocyclic aromatic ring which comprises 1, 2, 3 or 4 heteroatoms individually selected from nitrogen, oxygen and sulfur. The heteroaryl radical may be bonded to the rest of the molecule via a carbon atom or heteroatom. Examples of heteroaryl include, furyl, pyrrolyl, imidazolyl, thienyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridazinyl, pyrimidyl or pyridyl.
As used herein, except where explicitly stated otherwise, the term “heterocyclyl” or “heterocyclic” refers to a stable 3- to 6-membered non-aromatic monocyclic ring radical which comprises 1, 2, or 3 heteroatoms individually selected from nitrogen, oxygen and sulfur. The heterocyclyl radical may be bonded to the rest of the molecule via a carbon atom or heteroatom. Examples of heterocyclyl include, but are not limited to, pyrrolinyl, pyrrolidyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidyl, piperazinyl, tetrahydropyranyl, dihydroisoxazolyl, dioxolanyl, morpholinyl or δ-lactamyl.
As used herein, the term “heterocyclylC1-C2alkyl-” refers to a heterocyclyl ring as defined above attached to the rest of the molecule by a C1-C2alkylene radical as defined above.
As used herein, the term “heteroarylC1-C2alkyl-” refers to a heteroaryl ring as defined above attached to the rest of the molecule by a C1-C2alkylene radical as defined above.
As used herein, the term “phenylC1-C2alkyl-” refers to a phenyl ring attached to the rest of the molecule by a C1-C2alkylene radical as defined above. Examples of phenylC1-C2alkyl- include, but are not limited to, benzyl.
The presence of one or more possible asymmetric carbon atoms in a compound of formula (I) means that the compounds may occur in chiral isomeric forms, i.e., enantiomeric or diastereomeric forms. Also atropisomers may occur as a result of restricted rotation about a single bond. formula (I) is intended to include all those possible isomeric forms and mixtures thereof. The present invention includes all those possible isomeric forms and mixtures thereof for a compound of formula (I). Likewise, formula (I) is intended to include all possible tautomers (including lactam-lactim tautomerism and keto-enol tautomerism) where present. The present invention includes all possible tautomeric forms for a compound of formula (I). Similarly, where there are di-substituted alkenes, these may be present in E or Z form or as mixtures of both in any proportion. The present invention includes all these possible isomeric forms and mixtures thereof for a compound of formula (I).
The compounds of formula (I) will typically be provided in the form of an agronomically acceptable salt, a zwitterion or an agronomically acceptable salt of a zwitterion. This invention covers all such agronomically acceptable salts, zwitterions and mixtures thereof in all proportions.
For example a compound of formula (I) wherein Z comprises an acidic proton, may exist as a zwitterion, a compound of formula (I-I), or as an agronomically acceptable salt, a compound of formula (I-II) as shown below:
wherein, Y represents an agronomically acceptable anion and j and k represent integers that may be selected from 1, 2 or 3, dependent upon the charge of the respective anion Y.
A compound of formula (I) may also exist as an agronomically acceptable salt of a zwitterion, a compound of formula (I-III) as shown below:
wherein, Y represents an agronomically acceptable anion, M represents an agronomically acceptable cation (in addition to the pyridazinium cation) and the integers j, k and q may be selected from 1, 2 or 3, dependent upon the charge of the respective anion Y and respective cation M.
Thus where a compound of formula (I) is drawn in protonated form herein, the skilled person would appreciate that it could equally be represented in unprotonated or salt form with one or more relevant counter ions. The skilled person would also appreciate a nitrogen atom comprised in R1, R2, Q or X may also be protonated (for example see compound A12 in table A).
Suitable agronomically acceptable salts of the present invention, represented by an anion Y, include but are not limited to, chloride, bromide, iodide, fluoride, 2-naphthalenesulfonate, acetate, adipate, methoxide, ethoxide, propoxide, butoxide, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, butylsulfate, butylsulfonate, butyrate, camphorate, camsylate, caprate, caproate, caprylate, carbonate, citrate, diphosphate, edetate, edisylate, enanthate, ethanedisulfonate, ethanesulfonate, ethylsulfate, formate, fumarate, gluceptate, gluconate, glucoronate, glutamate, glycerophosphate, heptadecanoate, hexadecanoate, hydrogen sulfate, hydroxide, hydroxynaphthoate, isethionate, lactate, lactobionate, lau rate, malate, maleate, mandelate, mesylate, methanedisulfonate, methylsulfate, mucate, myristate, napsylate, nitrate, nonadecanoate, octadecanoate, oxalate, pelargonate, pentadecanoate, pentafluoropropionate, perchlorate, phosphate, propionate, propylsulfate, propylsulfonate, succinate, sulfate, tartrate, tosylate, tridecylate, triflate, trifluoroacetate, undecylinate and valerate.
Suitable cations represented by M include, but are not limited to, metals, conjugate acids of amines and organic cations. Examples of suitable metals include aluminium, calcium, cesium, copper, lithium, magnesium, manganese, potassium, sodium, iron and zinc. Examples of suitable amines include allylamine, ammonia, amylamine, arginine, benethamine, benzathine, butenyl-2-amine, butylamine, butylethanolamine, cyclohexylamine, decylamine, diamylamine, dibutylamine, diethanolamine, diethylamine, diethylenetriamine, diheptylamine, dihexylamine, diisoamylamine, diisopropylamine, dimethylamine, dioctylamine, dipropanolamine, dipropargylamine, dipropylamine, dodecylamine, ethanolamine, ethylamine, ethylbutylamine, ethylenediamine, ethylheptylamine, ethyloctylamine, ethylpropanolamine, heptadecylamine, heptylamine, hexadecylamine, hexenyl-2-amine, hexylamine, hexylheptylamine, hexyloctylamine, histidine, indoline, isoamylamine, isobutanolamine, isobutylamine, isopropanolamine, isopropylamine, lysine, meglumine, methoxyethylamine, methylamine, methylbutylamine, methylethylamine, methylhexylamine, methylisopropylamine, methylnonylamine, methyloctadecylamine, methylpentadecylamine, morpholine, N,N-diethylethanolamine, N-methylpiperazine, nonylamine, octadecylamine, octylamine, oleylamine, pentadecylamine, pentenyl-2-amine, phenoxyethylamine, picoline, piperazine, piperidine, propanolamine, propylamine, propylenediamine, pyridine, pyrrolidine, sec-butylamine, stearylamine, tallowamine, tetradecylamine, tributylamine, tridecylamine, trimethylamine, triheptylamine, trihexylamine, triisobutylamine, triisodecylamine, triisopropylamine, trimethylamine, tripentylamine, tripropylamine, tris(hydroxymethyl)aminomethane, and undecylamine. Examples of suitable organic cations include benzyltributylammonium, benzyltrimethylammonium, benzyltriphenylphosphonium, choline, tetrabutylammonium, tetrabutylphosphonium, tetraethylammonium, tetraethylphosphonium, tetramethylammonium, tetramethylphosphonium, tetrapropylammonium, tetrapropylphosphonium, tributylsulfonium, tributylsulfoxonium, triethylsulfonium, triethylsulfoxonium, trimethylsulfonium, trimethylsulfoxonium, tripropylsulfonium and tripropylsulfoxonium.
Preferred compounds of formula (I), wherein Z comprises an acidic proton, can be represented as either (I-I) or (I-II). For compounds of formula (I-II) emphasis is given to salts when Y is chloride, bromide, iodide, hydroxide, bicarbonate, acetate, pentafluoropropionate, triflate, trifluoroacetate, hydrogensulfate, methylsulfate, tosylate and nitrate, wherein j and k are 1. Preferably, Y is chloride, bromide, iodide, hydroxide, bicarbonate, acetate, trifluoroacetate, methylsulfate, tosylate and nitrate, wherein j and k are 1. For compounds of formula (I-II) emphasis is also given to salts when Y is carbonate and sulfate, wherein j is 2 and k is 1, and when Y is phosphate, wherein j is 3 and k is 1.
Where appropriate compounds of formula (I) may also be in the form of (and/or be used as) an N-oxide.
Compounds of formula (I) wherein m is 0 and n is 0 may be represented by a compound of formula (I-la) as shown below:
wherein R1, R2, R3, R4, R5, R8a, R8b and Z are as defined for compounds of formula (I).
Compounds of formula (I) wherein m is 1 and n is 0 may be represented by a compound of formula (I-Ib) as shown below:
wherein R1, R2, R1a, R2b, R3, R4, R5, R8a, R8b and Z are as defined for compounds of formula (I).
Compounds of formula (I) wherein m is 2 and n is 0 may be represented by a compound of formula (I-Ic) as shown below:
wherein R1, R2, R1a, R2b, R3, R4, R5, R8a, R8b and Z are as defined for compounds of formula (I).
Compounds of formula (I) wherein m is 3 and n is 0 may be represented by a compound of formula (I-Id) as shown below:
wherein R1, R2, R1a, R2b, R3, R4, R5, R8a, R8b and Z are as defined for compounds of formula (I).
The following list provides definitions, including preferred definitions, for substituents n, m, r, Q, X, Z, R1, R2, R1a, R2b, R2, R3, R4, R5, R6, R7, R7a, R7b, R7c, R7d, R7e, R8a, R8b, R9, R10, R11, R12, R13, R14, R15, R15a, R16, R17 and with reference to the compounds of formula (I) according to the invention. For any one of these substituents, any of the definitions given below may be combined with any definition of any other substituent given below or elsewhere in this document.
R1 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, C1-C6haloalkyl, —OR7, —OR15a, —N(R6)S(O)2R15, —N(R6)C(O)R15, —N(R6)C(O)OR15, —N(R6)C(O)NR16R17, —N(R6)CHO, —N(R7a)2 and —S(O)R15. Preferably, R1 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6fluoroalkyl, —NHS(O)2R15, —NHC(O)R15, —NHC(O)OR15, —NHC(O)NR16R17, —N(R7a)2 and —S(O)R15. More preferably, R1 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6fluoroalkyl, —OR7 and —N(R7a)2. Even more preferably, R1 is selected from the group consisting of hydrogen, C1-C6alkyl, —OR′ and —N(R7a)2. Even more preferably still, R1 is hydrogen or C1-C6alkyl. Yet even more preferably still, R1 is hydrogen or methyl. Most preferably R1 is hydrogen.
R2 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl and C1-C6haloalkyl. Preferably, R2 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl and C1-C6fluoroalkyl. More preferably, R2 is hydrogen or C1-C6alkyl. Even more preferably, R2 is hydrogen or methyl. Most preferably R2 is hydrogen.
Wherein when R1 is selected from the group consisting of —OR7, —OR15a, —N(R6)S(O)2R15, —N(R6)C(O)R15, —N(R6)C(O)OR15, —N(R6)C(O)NR16R17, —N(R6)CHO, —N(R7a)2 and —S(O)rR15, R2 is selected from the group consisting of hydrogen and C1-C6alkyl. Preferably, when R1 is selected from the group consisting of —OR7, —NHS(O)2R15, —NHC(O)R15, —NHC(O)OR15, —NHC(O)NR16R17, —N(R7a)2 and —S(O)rR15, R2 is selected from the group consisting of hydrogen and methyl.
Alternatively, R1 and R2 together with the carbon atom to which they are attached form a C3-C6cycloalkyl ring or a 3- to 6-membered heterocyclyl, which comprises 1 or 2 heteroatoms individually selected from N and O. Preferably, R1 and R2 together with the carbon atom to which they are attached form a C3-C6cycloalkyl ring. More preferably, R1 and R2 together with the carbon atom to which they are attached form a cyclopropyl ring.
In one embodiment R1 and R2 are hydrogen.
In another embodiment R1 is methyl and R2 is hydrogen.
In another embodiment R1 is methyl and R2 is methyl.
Q is (CR1aR2b)m.
m is 0, 1, 2 or 3. Preferably, m is 0, 1 or 2. More preferably, m is 1 or 2. Most preferably, m is 1.
Each R1a and R2b are independently selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, —OH, —OR7, —OR15a, —NH2, —NHR7, —NHR15a, —N(R6)CHO, —NR7bR7c and —S(O)rR15. Preferably, each R1a and R2b are independently selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6fluoroalkyl, —OH, —NH2 and —NHR7. More preferably, each R1a and R2b are independently selected from the group consisting of hydrogen, C1-C6alkyl, —OH and —NH2. Even more preferably, each R1a and R2b are independently selected from the group consisting of hydrogen, methyl, —OH and —NH2. Even more preferably still, each R1a and R2b are independently selected from the group consisting of hydrogen and methyl. Most preferably R1a and R2b are hydrogen.
In another embodiment each R1a and R2b are independently selected from the group consisting of hydrogen and C1-C6alkyl.
Alternatively, each R1a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl ring or a 3- to 6-membered heterocyclyl, which comprises 1 or 2 heteroatoms individually selected from N and O. Preferably, each R1a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl ring. More preferably, each R1a and R2b together with the carbon atom to which they are attached form a cyclopropyl ring.
R3, R4 and R5 are independently selected from the group consisting of hydrogen, cyano, nitro, C1-C6alkyl, C1-C6thioalkyl, C1-C6fluoroalkyl, C1-C6fluoroalkoxy, C1-C6alkoxy, C3-C6cycloalkyl, phenyl and —N(R6)2. Preferably, R3, R4 and R5 are independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6fluoroalkoxy, C1-C6alkoxy, C3-C6cycloalkyl, phenyl and —N(R6)2. More preferably, R3, R4 and R5 are independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy and phenyl. Even more preferably, R3, R4 and R5 are independently selected from the group consisting of hydrogen, C1-C6alkyl and phenyl. Even more preferably still, R3, R4 and R5 are independently selected from the group consisting of hydrogen, methyl and phenyl. Most preferably, R3, R4 and R5 are hydrogen.
In one embodiment R3 is hydrogen and R4 and R5 are selected from the group consisting of hydrogen, methyl and phenyl.
Each R6 is independently selected from hydrogen and C1-C6alkyl. Preferably, each R6 is independently selected from hydrogen and methyl.
Each R7 is independently selected from the group consisting of C1-C6alkyl, —S(O)2R15, —C(O)R15, —C(O)OR16 and —C(O)NR16R17. Preferably, each R7 is independently selected from the group consisting of C1-C6alkyl, —C(O)R15 and —C(O)NR16R17. More preferably, each R7 is C1-C6alkyl. Most preferably, each R7 is methyl.
Each R7a is independently selected from the group consisting of —S(O)2R15, —C(O)R15, —C(O)OR15, —C(O)NR16R17 and —C(O)NR6R15a. Preferably, each R7a is independently —C(O)R15 or —C(O)NR16R17.
R7b and R7c are independently selected from the group consisting of C1-C6alkyl, —S(O)2R15, —C(O)R15, —C(O)OR16, —C(O)NR16R17 and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different. Preferably, R7b and R7c are independently selected from the group consisting of C1-C6alkyl, —C(O)R15 and —C(O)NR16R17. More preferably, R7b and R7c are C1-C6alkyl. Most preferably, R7b and R7c are methyl.
Alternatively, R7b and R7c together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl ring which optionally comprises one additional heteroatom individually selected from N, O and S. Preferably, R7b and R7c together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocyclyl ring which optionally comprises one additional heteroatom individually selected from N and O. More preferably, R7b and R7c together with the nitrogen atom to which they are attached form an pyrrolidyl, oxazolidinyl, imidazolidinyl, piperidyl, piperazinyl or morpholinyl group.
R7d and R7e are independently selected from the group consisting of hydrogen, C1-C6alkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, C1-C3alkoxyC1-C3alkyl-, C2-C6alkynyl, —S(O)2R15, —C(O)R16, —C(O)OR16, —C(O)NR16R17 and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents. Preferably, R7d and R7e are independently selected from the group consisting of hydrogen, C1-C6alkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, C1-C3alkoxyC1-C3alkyl-, C2-C6alkynyl, —C(O)R15 and —C(O)OR16. More preferably, R7d and R7e are independently selected from the group consisting of hydrogen, C1-C6alkyl, C3-C6cycloalkylC1-C3alkyl-, C1-C3alkoxyC1-C3alkyl-, C2-C6alkynyl, —C(O)R15 and —C(O)OR16. Even more preferably, R7d and R7e are independently selected from the group consisting of hydrogen, C1-C6alkyl, —C(O)R15 and —C(O)OR16. Even more preferably still, R7d and R7e are independently selected from the group consisting of hydrogen, methyl, —C(O)Me and —C(O)(013u).
R8a is selected from the group consisting of hydrogen, —OH, —OR7, —S(O)rR15, —C(O)OR10, —C(O)R15, —C(O)NR16R17, —S(O)2NR16R17, —NR7dR7e, R16S(O)rC1-C3alkyl-, R16R17NS(O)2C1-C3alkyl-, R16C(O)C1-C3alkyl-, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6cycloalkoxy, C3-C6cycloalkylC1-C3alkyl-, C3-C6cycloalkylC1-C3alkoxy-, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, cyanoC1-C6alkyl-, C1-C3alkoxyC1-C3alkoxy-, C1-C6haloalkoxy, C1-C3haloalkoxyC1-C3alkyl-, C3-C6alkenyloxy, C3-C6alkynyloxy, —C(R6)═NOR6, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S(O)r, heteroaryl and heteroarylC1-C2alkyl-, wherein the heteroaryl is a 5- or 6-membered aromatic ring, which comprises 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and wherein said C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, heteroaryl or heteroarylC1-C2alkyl-, are optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different.
Preferably, R8a is selected from the group consisting of —NR7dR7e, R16S(O)rC1-C3alkyl-, R16R17NS(O)2C1-C3alkyl-, R15C(O)C1-C3alkyl-, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, C2-C6alkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, cyanoC1-C6alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S(O)r, heteroaryl and heteroarylC1-C2alkyl-, wherein the heteroaryl is a 5- or 6-membered aromatic ring, which comprises 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and wherein said C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, heteroaryl or heteroarylC1-C2alkyl-, are optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different.
More preferably, R8a is selected from the group consisting of —NR7dR7e, R15S(O)rC1-C3alkyl-, R16R17NS(O)2C1-C3alkyl-, R16C(O)C1-C3alkyl-, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, C2-C6alkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, cyanoC1-C6alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S(O)r, heteroaryl and heteroarylC1-C2alkyl-, wherein the heteroaryl is a 5- or 6-membered aromatic ring, which comprises 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and wherein said C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, heteroaryl or heteroarylC1-C2alkyl-, are optionally substituted by 1 or 2 R9 substituents, which may be the same or different.
Even more preferably, R8a is selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, C2-C6alkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, cyanoC1-C6alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S(O)r, heteroaryl and heteroarylC1-C2alkyl-, wherein the heteroaryl is a 5- or 6-membered aromatic ring, which comprises 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and wherein said C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, heteroaryl or heteroarylC1-C2alkyl- are optionally substituted by 1 R9 substituent.
Even more preferably still, R8a is selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, cyanoC1-C3alkyl-, phenyl and heterocyclyl, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1 S(O), heteroatom, and wherein said phenyl is optionally substituted by 1 R9 substituent.
Yet even more preferably still, R8a is selected from the group consisting of methyl, ethyl, iso-propyl, n-propyl, n-butyl, iso-butyl, tert-butyl, 2,2,2-trifluoroethyl-, allyl, propargyl, 1-methylprop-2-ynyl, 1,1-dimethylprop-2-ynyl, 2-methoxyethyl-, 1-cyano-1-methyl-ethyl-, phenyl, 2-hydroxyphenyl, thietan-3-yl, 1-oxothietan-3-yl and 1,1,-dioxothietan-3-yl.
In one embodiment R8a is selected from the group consisting of tert-butoxycarbonyl(methyl)amino-, acetamido, 2-methylsulfanylethyl-, 2-ethylsulfanylethyl, 2-methylsulfinylethyl, 2-ethylsulfinylethyl, 2-methylsulfonylethyl, 2-ethylsulfonylethyl, (1-methyl-2-methylsulfonyl-ethyl), 2-(dimethylsulfamoyl)ethyl, 2-(methylsulfamoyl)ethyl, acetonyl, 3-oxobutyl, methyl, ethyl, iso-propyl, n-propyl, n-butyl, iso-butyl, tert-butyl, 2,2,2-trifluoroethyl-, 2,2,3,3,3-pentafluoropropyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclopropylmethyl-, (1-methylcyclopropyl), (2-m ethylcyclopropyl), (1-ethylcyclopropyl), (2,2-dimethylcyclopropyl), [1-(trifluoromethyl)cyclopropyl], (2,2-difluorocyclopropyl), 1-cyanocyclopropyl-, (2-hydroxy-1,1-dimethyl-ethyl), (2-hydroxy-1-methyl-ethyl), 3-hydroxybutyl, 2-hydroxypropyl, 1-cyanoethyl-, cyanomethyl-, 2-cyanoethyl-, allyl, propargyl, 1-methylprop-2-ynyl, 1,1-dimethylprop-2-ynyl, but-2-ynyl, but-3-ynyl, 2-methoxyethyl-, (2-methoxy-1-methyl-ethyl), 2-hydroxyethyl-, 1-cyano-1-methyl-ethyl-, phenyl, 2-hydroxyphenyl, (2,4-difluorophenyl), benzyl, 4-fluorobenzyl, 4-cyanobenzyl, 4-trifluoromethylbenzyl, (5,5-dimethyl-4H-isoxazol-3-yl), 2-(5,5-dimethyl-4H-isoxazol-3-yl)ethyl, thietan-3-yl, 1-oxothietan-3-yl, 1,1,-dioxothietan-3-yl, 2-pyridylmethyl, 2-pyrimidin-2-ylethyl, pyrazin-2-yl, (2-m ethylpyrazol-3-yl), isoxazol-3-yl, thiazol-2-ylmethyl, 2-thiazol-2-ylethyl, (1-methyl-1,2,4-triazol-3-yl)methyl, 2-(2-methyl-1,2,4-triazol-3-yl)ethyl, and thiazol-2-yl. Preferably, R8a is selected from the group consisting of tert-butoxycarbonyl(methyl)amino-, 2-methylsulfanylethyl-, methyl, ethyl, iso-propyl, n-propyl, n-butyl, iso-butyl, tert-butyl, 2,2,2-trifluoroethyl-, cyclopropyl, cyclopentyl, cyclohexyl, cyclopropylmethyl-, 1-cyanocyclopropyl-, allyl, propargyl, 1-methylprop-2-ynyl, 1,1-dimethylprop-2-ynyl, 2-methoxyethyl-, 2-hydroxyethyl-, 1-cyano-1-methyl-ethyl-, phenyl, 2-hydroxyphenyl, benzyl, 4-fluorobenzyl, thietan-3-yl, 1-oxothietan-3-yl, 1,1,-dioxothietan-3-yl, isoxazol-3-yl and thiazol-2-yl.
R8b is selected from the group consisting of hydrogen, —OR7, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6halocycloalkyl, C3-C6cycloalkoxy, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, C1-C3alkoxyC1-C3alkoxy-, C1-C6haloalkoxy, C1-C3haloalkoxyC1-C3alkyl-, C3-C6alkenyloxy and C3-C6alkynyloxy. Preferably, R8b is selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl- and C1-C3alkoxyC1-C3alkoxy-. More preferably, R8b is selected from the group consisting of hydrogen, C1-C6alkyl and C2-C3alkynyl. Even more preferably, R8b is selected from the group consisting of hydrogen and C1-C6alkyl. Even more preferably still, R8b is selected from the group consisting of hydrogen, methyl and iso-propyl.
Alternatively, R8a and R8b together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl, which optionally comprises 1 or 2 additional heteroatoms independently selected from N, O and S(O)r, and wherein said heterocyclyl moiety is optionally substituted by 1 or 2 R9 substituents, which may be the same or different. Preferably, R8a and R8b together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl, which optionally comprises 1 or 2 additional heteroatoms independently selected from N, O and S(O)r, and wherein said heterocyclyl moiety is optionally substituted by 1 R9 substituent. More preferably, R8a and R8b together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocyclyl, which optionally comprises 1 or 2 additional heteroatoms independently selected from N, O and S(O)r, and wherein said heterocyclyl moiety is optionally substituted by 1 R9 substituent. Even more preferably, R8a and R8b together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocyclyl, which optionally comprises 1 additional heteroatom selected from N, O and S(O)r, and wherein said heterocyclyl moiety is optionally substituted by 1 R9 substituent. Even more preferably still, R8a and R8b together with the nitrogen atom to which they are attached form a group selected from methylpiperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, (1-oxo-1,4-thiazinan-4-yl), (1,1-dioxo-1,4-thiazinan-4-yl) and thiomorpholinyl. Most preferably, R8a and R8b together with the nitrogen atom to which they are attached form a group selected from piperidinyl, pyrrolidinyl and morpholinyl.
In one embodiment R8a and R8b together with the nitrogen atom to which they are attached form a 5- to 6- membered heterocyclyl, which optionally comprises 1 additional heteroatom selected from N, O and S(O), preferably O.
Each R9 is independently selected from the group consisting of halogen, cyano, —OH, —N(R6)2, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl and C1-C4haloalkoxy. Preferably, each R9 is independently selected from the group consisting of halogen, cyano, —OH, —N(R6)2, C1-C4alkyl, C1-C4alkoxy, C1-C4haloalkyl and C1-C4haloalkoxy. More preferably, each R9 is independently selected from the group consisting of halogen, cyano, —OH, C1-C4alkyl, C1-C4alkoxy and C1-C4haloalkyl. Even more preferably, each R9 is independently selected from the group consisting of halogen, cyano, —OH and C1-C4alkyl. Yet even more preferably, each R9 is cyano or —OH.
In one embodiment each R9 is independently selected from the group consisting of fluoro, cyano, —OH, methyl and CF3.
X is selected from the group consisting of C3-C6cycloalkyl, phenyl, a 5- or 6-membered heteroaryl, which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S, and a 4- to 6-membered heterocyclyl, which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S, and wherein said cycloalkyl, phenyl, heteroaryl or heterocyclyl moieties are optionally substituted by 1 or 2 substituents, which may be the same or different, selected from R9, and wherein the aforementioned CR1R2, Q and Z moieties may be attached at any position of said cycloalkyl, phenyl, heteroaryl or heterocyclyl moieties.
Preferably, X is selected from the group consisting of phenyl and a 4- to 6-membered heterocyclyl, which comprises 1 or 2 heteroatoms individually selected from N and O, and wherein said phenyl or heterocyclyl moieties are optionally substituted by 1 or 2 substituents, which may be the same or different, selected from R9, and wherein the aforementioned CR1R2, Q and Z moieties may be attached at any position of said phenyl or heterocyclyl moieties.
More preferably, X is a 4- to 6-membered heterocyclyl, which comprises 1 or 2 heteroatoms individually selected from N and O, and wherein said heterocyclyl moieties is optionally substituted by 1 or 2 substituents, which may be the same or different, selected from R9, and wherein the aforementioned CR1R2, Q and Z moieties may be attached at any position of said heterocyclyl moiety.
In one embodiment, X is a 5-membered heterocyclyl, which comprises 1 heteroatom, wherein said heteroatom is N, and wherein the aforementioned CR1R2, Q and Z moieties may be attached at any position of said heterocyclyl moiety. Preferably, X is a 5-membered heterocyclyl, which comprises 1 heteroatom, wherein said heteroatom is N, and wherein the aforementioned CR1R2 and Q moieties are attached adjacent to the N atom and the Z moiety is attached to the N atom.
In another embodiment, X is phenyl optionally substituted by 1 or 2 substituents, which may be the same or different, selected from R9, and wherein the aforementioned CR1R2, Q and Z moieties may be attached at any position of said phenyl moiety. Preferably, X is phenyl and the aforementioned CR1R2 and Q moieties are attached in a position para to the Z moiety.
n is 0 or 1. Preferably, n is O.
Z is selected from the group consisting of —C(O)OR10, —CH2OH, —CHO, —C(O)NHOR11, —C(O)NHCN, —OC(O)NHOR11, —OC(O)NHCN, —NR6C(O)NHOR11, —NR6C(O)NHCN, —C(O)NHS(O)2R12, —OC(O)NHS(O)2R12, —NR6C(O)NHS(O)2R12, —S(O)2OR10, —OS(O)2OR10, —NR6S(O)2OR10, —NR6S(O)OR10, —NHS(O)2R14, —S(O)OR10, —OS(O)OR10, —S(O)2NHCN, —S(O)2NHC(O)R18, —S(O)2NHS(O)2R12, —OS(O)2NHCN, —OS(O)2NHS(O)2R12, —OS(O)2NHC(O)R18, —NR6S(O)2NHCN, —NR6S(O)2NHC(O)R18, —N(OH)C(O)R15, —ONHC(O)R10, —NR6S(O)2NHS(O)2R12, —P(O)(R13)(OR10), —P(O)H(OR10), —OP(O)(R13)(OR10), —NR6P(O)(R13)(OR10) and tetrazole.
Preferably, Z is selected from the group consisting of —C(O)OR10, —C(O)NHOR11, —OC(O)NHOR11, —NR6C(O)NHOR11, —C(O)NHS(O)2R12, —OC(O)NHS(O)2R12, —NR6C(O)NHS(O)2R12, —S(O)2OR10, —OS(O)2OR10, —NR6S(O)2OR10, —NR6S(O)OR10, —NHS(O)2R14, —S(O)OR10, —OS(O)OR10, —S(O)2NHC(O)R10, —S(O)2NHS(O)2R12, —OS(O)2NHS(O)2R12, —OS(O)2NHC(O)R18, —NR6S(O)2NHC(O)R18, —N(OH)C(O)R15, —ON HC(O)R10, —NR6S(O)2NHS(O)2R12, —P(O)(R13)(OR10), —P(O)H(OR10), —OP(O)(R13)(OR10) and —NR6P(O)(R13)(OR10).
More preferably, Z is selected from the group consisting of —C(O)OR10, —C(O)NHOR11, —C(O)NHS(O)2R12, —S(O)2OR10, —OS(O)2OR10, —NR6S(O)2OR10, —NHS(O)2R14, —S(O)OR10 and —P(O)(R13)(OR10).
Even more preferably, Z is selected from the group consisting of —C(O)OR10, —S(O)2OR10, —OS(O)2OR10, —NR6S(O)2OR10, —NHS(O)2R14 and —P(O)(R13)(OR10).
Even more preferably still, Z is selected from the group consisting of —C(O)OR10, —S(O)2OR10, —OS(O)2OR10, —NR6S(O)2OR10 and —NHS(O)2R14.
Yet even more preferably still, Z is selected from the group consisting of —C(O)OH, —C(O)OCH3, —S(O)2OH, —OS(O)2OH, —NHS(O)2OH and —NHS(O)2CF3.
Most preferably Z is —C(O)OH or —S(O)2OH.
In one embodiment Z is selected from the group consisting of —C(O)OH, —C(O)OCH3, —S(O)2OH, —OS(O)2OH, —NHS(O)2OH, NHS(O)2CF3, —P(O)(OCH2CH3)(OCH2CH3) and —P(O)(OH)(OH).
R10 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl and benzyl, and wherein said phenyl or benzyl are optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different. Preferably, R10 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl and benzyl. More preferably, R10 is selected from the group consisting of hydrogen and C1-C6alkyl. Most preferably, R10 is hydrogen.
R11 is selected from the group consisting of hydrogen, C1-C6alkyl and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different. Preferably, R11 is selected from the group consisting of hydrogen, C1-C6alkyl and phenyl. More preferably, R11 is selected from the group consisting of hydrogen and C1-C6alkyl. Even more preferably, R11 is C1-C6alkyl. Most preferably, R11 is methyl.
R12 is selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, —OH, —N(R6)2 and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different. Preferably, R12 is selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, —OH, —N(R6)2 and phenyl. More preferably, R12 is selected from the group consisting of C6alkyl, C1-C6haloalkyl and —N(R6)2. Even more preferably, R12 is selected from the group consisting of methyl, —N(Me)2 and trifluoromethyl. Most preferably, R12 is methyl.
R13 is selected from the group consisting of —OH, C1-C6alkyl, C1-C6alkoxy and phenyl. Preferably R13 is selected from the group consisting of —OH, C1-C6alkyl and C1-C6alkoxy. More preferably, R13 is selected from the group consisting of —OH and C1-C6alkoxy. Even more preferably, R13 is selected from the group consisting of —OH, methoxy and ethoxy. Most preferably, R13 is —OH.
R14 is C1-C6haloalkyl. Preferably, R14 is trifluoromethyl.
R15 is selected from the group consisting of C1-C6alkyl and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different. Preferably, R15 is selected from the group consisting of C1-C6alkyl and phenyl. More preferably, R15 is C1-C6alkyl. Even more preferably, R15 is methyl or ethyl. Most preferably, R15 is methyl.
R15a is phenyl, wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different. Preferably, R15a is phenyl optionally substituted by 1 R9 substituent. More preferably, R15a is phenyl.
R16 and R17 are independently selected from the group consisting of hydrogen and C1-C6alkyl. Preferably, R16 and R17 are independently selected from the group consisting of hydrogen and methyl.
Alternatively, R16 and R17 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl ring which optionally comprises one additional heteroatom individually selected from N, O and S. Preferably, R16 and R17 together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocyclyl ring which optionally comprises one additional heteroatom individually selected from N and O. More preferably, R16 and R17 together with the nitrogen atom to which they are attached form an pyrrolidyl, oxazolidinyl, imidazolidinyl, piperidyl, piperazinyl or morpholinyl group.
R18 is selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, —N(R6)2 and phenyl, and wherein said phenyl is optionally substituted by 1, 2 or 3 R9 substituents, which may be the same or different. Preferably, R18 is selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, —N(R6)2 and phenyl. More preferably, R18 is selected from the group consisting of hydrogen, C1-C6alkyl and C1-C6haloalkyl. Further more preferably, R18 is selected from the group consisting of C1-C6alkyl and C1-C6haloalkyl. Most preferably, R18 is methyl or trifluoromethyl.
r is 0, 1 or 2. Preferably, r is 0 or 2.
In a set of preferred embodiments, in a compound according to formula (I) of the invention,
R1 is hydrogen or C1-C6alkyl;
R2 is hydrogen or methyl;
Q is (CR1aR2b)m;
m is 0, 1 or 2;
R1a and R2b are independently selected from the group consisting of hydrogen, C1-C6alkyl, —OH and —NH2;
R3, R4 and R5 are independently selected from the group consisting of hydrogen, C1-C6alkyl and phenyl; each R6 is independently selected from hydrogen and methyl;
R7d and R7e are independently selected from the group consisting of hydrogen, C1-C6alkyl, —C(O)R15 and —C(O)OR15;
R8a is selected from the group consisting of —NR7dR7e, R15S(O)rC1-C3alkyl-, R16R17NS(O)2C1-C3alkyl-, R15C(O)C1-C3alkyl-, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, C2-C6alkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, cyanoC1-C6alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S(O)r, heteroaryl and heteroarylC1-C2alkyl-, wherein the heteroaryl is a 5- or 6-membered aromatic ring, which comprises 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and wherein said C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, heteroaryl or heteroarylC1-C2alkyl-, are optionally substituted by 1 or 2 R9 substituents, which may be the same or different;
R8b is selected from the group consisting of hydrogen, C1-C6alkyl and C2-C3alkynyl; or
R8a and R8b together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl, which optionally comprises 1 or 2 additional heteroatoms independently selected from N, O and S(O)r, and wherein said heterocyclyl moiety is optionally substituted by 1 R9 substituents; and R9 is independently selected from the group consisting of halogen, cyano, —OH, C1-C4alkyl, C1-C4alkoxy and C1-C4haloalkyl;
n is 0;
Z is selected from the group consisting of —C(O)OR10, —S(O)2OR10, —OS(O)2OR10, —NR6S(O)2OR10, —NHS(O)2R14 and —P(O)(R13)(OR10);
R10 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl and benzyl;
R13 is selected from the group consisting of —OH and C1-C6alkoxy;
R14 is trifluoromethyl;
R15 is C1-C6alkyl;
R16 and R17 are independently selected from the group consisting of hydrogen and methyl; and
r is 0, 1 or 2.
Preferably,
R1 is hydrogen or methyl;
R2 is hydrogen or methyl;
Q is (CR1aR2b)m;
m is 0, 1 or 2;
R1a and R2b are independently selected from the group consisting of hydrogen, methyl, —OH and —NH2;
R3, R4 and R5 are independently selected from the group consisting of hydrogen, methyl and phenyl;
each R6 is independently selected from hydrogen and methyl;
R7d and R7e are independently selected from the group consisting of hydrogen, methyl, —C(O)Me and —C(O)(OtBu);
R8a is selected from the group consisting of —NR7aR7e, R15S(O)rC1-C3alkyl-, R16R17NS(O)2C1-C3alkyl-, R15C(O)C1-C3alkyl-, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, C2-C6alkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, cyanoC1-C6alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S(O)r, heteroaryl and heteroarylC1-C2alkyl-, wherein the heteroaryl is a 5- or 6-membered aromatic ring, which comprises 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and wherein said C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, heteroaryl or heteroarylC1-C2alkyl-, are optionally substituted by 1 or 2 R9 substituents, which may be the same or different;
R8b is selected from the group consisting of hydrogen, methyl and iso-propyl; or
R8a and R8b together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocyclyl, which optionally comprises 1 or 2 additional heteroatoms independently selected from N, O and S(O)r, and wherein said heterocyclyl moiety is optionally substituted by 1 R9 substituent; and
R9 is independently selected from the group consisting of fluoro, cyano, —OH, methyl and CF3;
n is 0;
Z is selected from the group consisting of —C(O)OH, —C(O)OCH3, —S(O)2OH, —OS(O)2OH, —NHS(O)2OH, NHS(O)2CF3, —P(O)(OCH2CH3)(OCH2CH3) and —P(O)(OH)(OH);
R15 is methyl or ethyl;
R16 and R17 are independently selected from the group consisting of hydrogen and methyl; and
r is 0, 1 or 2.
In another set of preferred embodiments, in a compound according to formula (I) of the invention,
R1 is hydrogen or C1-C6alkyl;
R2 is hydrogen or methyl;
Q is (CR1aR2b)m;
m is 0, 1 or 2;
R1a and R2b are independently selected from the group consisting of hydrogen, C1-C6alkyl, —OH and —NH2;
R3, R4 and R5 are independently selected from the group consisting of hydrogen, C1-C6alkyl and phenyl;
each R6 is independently selected from hydrogen and methyl;
R8a is selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, C2-C6alkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, hydroxyC1-C6alkyl-, cyanoC1-C6alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S(O)r, heteroaryl and heteroarylC1-C2alkyl-, wherein the heteroaryl is a 5- or 6-membered aromatic ring, which comprises 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and wherein said C3-C6cycloalkyl, C3-C6cycloalkylC1-C3alkyl-, phenyl, phenylC1-C2alkyl-, heterocyclyl, heterocyclylC1-C2alkyl-, heteroaryl or heteroarylC1-C2alkyl- are optionally substituted by 1 R9 substituent;
R8b is selected from the group consisting of hydrogen, C1-C6alkyl and C2-C3alkynyl; or
R8a and R8b together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocyclyl, which optionally comprises 1 additional O heteroatom; and
R9 is independently selected from the group consisting of halogen, cyano, —OH and C1-C4alkyl;
n is 0;
Z is selected from the group consisting of —C(O)OR10, —S(O)2OR10, —OS(O)2OR10, —NR6S(O)2OR10 and —NHS(O)2R14;
R10 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl and benzyl;
R14 is trifluoromethyl; and
r is 0, 1 or 2.
Preferably,
R1 is hydrogen or methyl;
R2 is hydrogen or methyl;
Q is (CR1aR2b)m;
m is 1 or 2;
R1a and R2b are independently selected from the group consisting of hydrogen and methyl;
R3, R4 and R5 are independently selected from the group consisting of hydrogen, methyl and phenyl;
each R6 is independently selected from hydrogen and methyl;
R8a is selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C3alkoxyC1-C3alkyl-, cyanoC1-C3alkyl-, phenyl and heterocyclyl, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1 S(O), heteroatom, and wherein said phenyl is optionally substituted by 1 R9 substituent;
R8b is selected from the group consisting of hydrogen and C1-C6alkyl;
R9 is cyano or —OH;
n is 0; and
Z is selected from the group consisting of C(O)OH, —C(O)OCH3, —S(O)2OH, —OS(O)2OH, —NHS(O)2OH and —NHS(O)2CF3.
In one set of preferred embodiments, the compound according to formula (I) is selected from a compound of formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f) or (I-g),
wherein in a compound of formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f) or (I-g),
R9a is selected from the group consisting of C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, C3alkoxyC1-C3alkyl-, cyanoC1-C3alkyl-, phenyl and heterocyclyl, wherein the heterocyclyl moiety is a 4- to 6-membered saturated or partially saturated ring which comprises 1 S(O)r heteroatom, and wherein said phenyl is optionally substituted by 1 R9 substituent;
R8b is selected from the group consisting of hydrogen and C1-C6alkyl;
R9 is cyano or —OH; and
Z is selected from the group consisting of C(O)OH, —C(O)OCH3, —S(O)2OH, —OS(O)2OH, —NHS(O)2OH and —NHS(O)2CF3.
In another set of embodiments, the compound according to formula (I) is selected from a compound A1 to A148 listed in Table A.
It should be understood that compounds of formula (I) may exist/be manufactured in ‘procidal form’, wherein they comprise a group ‘G’. Such compounds are referred to herein as compounds of Formula (I-IV).
G is a group which may be removed in a plant by any appropriate mechanism including, but not limited to, metabolism and chemical degradation to give a compound of formula (I-I), (I-II) or (I-III) wherein Z contains an acidic proton, for example see the scheme below:
Whilst such G groups may be considered as ‘procidal’, and thus yield active herbicidal compounds once removed, compounds comprising such groups may also exhibit herbicidal activity in their own right. In such cases in a compound of formula (I-IV), Z-G may include but is not limited to, any one of (G1) to (G7) below and E indicates the point of attachment to the remaining part of a compound of formula (I):
In embodiments where Z-G is (G1) to (G7), G, R19, R20, R21, R22 and R23 are defined as follows:
G is C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, —C(R21R22)OC(O)R10, phenyl or phenyl-C1-C4alkyl-, wherein said phenyl moiety is optionally substituted by 1 to 5 substituents independently selected from halo, cyano, nitro, C1-C6alkyl, C1-C6haloalkyl or C1-C6alkoxy.
R19 is C1-C6alkyl or phenyl,
R20 is hydroxy, C1-C6alkyl, C1-C6alkoxy or phenyl,
R21 is hydrogen or methyl,
R22 is hydrogen or methyl,
R23 is hydrogen or C1-C6alkyl.
The compounds in Tables 1 to 20 below illustrate the compounds of the invention. The skilled person would understand that the compounds of formula (I) may exist as an agronomically acceptable salt, a zwitterion or an agronomically acceptable salt of a zwitterion as described hereinbefore.
This table discloses 53 specific compounds of the formula (T-1):
Wherein m, Q, R3, R4, R5 and Z are as defined in Table 1, R1 and R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-2):
Wherein m, Q, R3, R4, R5 and Z are as defined in Table 2, R1 and R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-3):
wherein m, Q, R3, R4, R5 and Z are as defined in Table 3, R1 and R2 are hydrogen and n is 0.
This table discloses 53 specific compounds of the formula (T-4):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 1, R1 and R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-5):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 2, R1 and R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-6):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 3, R1 and R2 are hydrogen and n is 0.
This table discloses 53 specific compounds of the formula (T-7):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 1, R1 and R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-8):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 2, Wand R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-9):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 3, Wand R2 are hydrogen and n is 0.
This table discloses 53 specific compounds of the formula (T-10):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 1, Wand R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-11):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 2, R1 and R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-12):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 3, R1 and R2 are hydrogen and n is 0.
This table discloses 53 specific compounds of the formula (T-13):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 1, R1 and R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-14):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 2, Wand R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-15):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 3, Wand R2 are hydrogen and n is 0.
This table discloses 53 specific compounds of the formula (T-16):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 1, Wand R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-17):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 2, R1 and R2 are hydrogen and n is 0.
This table discloses 49 specific compounds of the formula (T-18):
wherein m, Q, R3, R4, R5 and Z are as defined above in Table 3, R1 and R2 are hydrogen and n is 0.
This table discloses 17 specific compounds of the formula (T-19):
wherein R8a and R8b are as defined in Table 19, R3, R4 and R5 are hydrogen.
This table discloses 17 specific compounds of the formula (T-20):
wherein R8 and R8b are as defined in Table 20, R3, R4 and R5 are hydrogen.
The compounds of the present invention may be prepared according to the following schemes in which the substituents n, m, r, Q, X, Z, R1, R2, R1a, R2b, R2, R3, R4, R5, R6, R7, R7a, R7b, R7c, R7d, R7e, R8a, R8b, R9, R10, R11, R12, R13, R14, R15, R15a, R16, R17 and are as defined hereinbefore unless explicitly stated otherwise. The compounds of the preceeding Tables 1 to 20 may thus be obtained in an analogous manner.
The compounds of formula (I) may be prepared by the alkylation of compounds of formula (X), wherein R3, R4, R5, R8a and R8b are as defined for compounds of formula (I), with a suitable alkylating agent of formula (W), wherein R1, R2, Q, X, n and Z are as defined for compounds of formula (I) and LG is a suitable leaving group, for example, halide or pseudohalide such as triflate, mesylate or tosylate, in a suitable solvent at a suitable temperature, as described in reaction scheme 1. Example conditions include stirring a compound of formula (X) with an alkylating agent of formula (W) in a solvent, or mixture of solvents, such as acetone, dichloromethane, dichloroethane, N,N-dimethylformamide, acetonitrile, 1,4-dioxane, water, acetic acid or trifluoroacetic acid at a temperature between −78° C. and 150° C. Alkylating agents of formula (W) are commercially available or are known in the literature and may include, but are not limited to, bromoacetic acid, methyl bromoacetate, 3-bromopropionoic acid, methyl 3-bromopropionate, 2-bromo-N-methoxyacetamide, sodium 2-bromoethanesulphonate, 2,2-dimethylpropyl 2-(trifluoromethylsulfonyloxy)ethanesulfonate, 2-bromo-N-methanesulfonylacetamide, 3-bromo-N-methanesulfonylpropanamide, dimethoxyphosphorylmethyl trifluoromethanesulfonate, dimethyl 3-bromopropylphosphonate, 3-chloro-2,2-dimethyl-propanoic acid and diethyl 2-bromoethylphosphonate. Such alkylating agents and related compounds are either known in the literature or may be prepared by known literature methods. Compounds of formula (I) which may be described as esters of N-alkyl acids, which include, but are not limited to, esters of carboxylic acids, phosphonic acids, phosphinic acids, sulfonic acids and sulfinic acids, may be subsequently partially or fully hydrolysed by treatment with a suitable reagent, for example, aqueous hydrochloric acid or trimethylsilyl bromide, in a suitable solvent at a suitable temperature between 0° C. and 100° C.
Additionally, compounds of formula (I) may be prepared by reacting compounds of formula (X), wherein R3, R4, R5, R8a and R8b are as defined for compounds of formula (I), with a suitably activated electrophilic alkene of formula (B), wherein R1, R2 and R1a are as defined for compounds of formula (I) and Z is —S(O)2OR10, —P(O)(R13)(OR10) or —C(O)OR10, in a suitable solvent at a suitable temperature, as described in reaction scheme 2. Suitable solvents and suitable temperatures are as previously described. Compounds of formula (B) are known in the literature, or may be prepared by known methods. Example reagents include, but are not limited to, acrylic acid, methacrylic acid, crotonic acid, 3,3-dimethylacrylic acid, methyl acrylate, ethene sulfonic acid, isopropyl ethylenesulfonate, 2,2-dimethylpropyl ethenesulfonate and dimethyl vinylphosphonate. The direct products of these reactions, which may be described as esters of N-alkyl acids, which include, but are not limited to, esters of carboxylic acids, phosphonic acids, phosphinic acids, sulfonic acids and sulfinic acids, may be subsequently partially or fully hydrolysed by treatment with a suitable reagent in a suitable solvent at a suitable temperature, as described in reaction scheme 2.
In a related reaction compounds of formula (I), wherein Q is C(R1aR2b), m is 1, 2 or 3, n=0 and Z is —S(O)2OH, —OS(O)2OH or —NR5S(O)2OR10, may be prepared by the reaction of compounds of formula (X), wherein R3, R4, R5, R8a and R8b are as defined for compounds of formula (I), with a cyclic alkylating agent of formula (E), (F) or (AF), wherein Y is, C(R1aR2b), O or NR6 and R1, R2, R1a and R2b are as defined for compounds of formula (I), in a suitable solvent at a suitable temperature, as described in reaction scheme 3. Suitable solvents and suitable temperatures are as previously described. An alkylating agent of formula (E) or (F) may include, but is not limited to, 1,3-propanesultone, 1,4-butanesultone, ethylenesulfate, 1,3-propylene sulfate and 1,2,3-oxathiazolidine 2,2-dioxide. Such alkylating agents and related compounds are either known in the literature or may be prepared by known literature methods.
A compound of formula (I), wherein m is 0, n is 0, Z is —S(O)2OH and R3, R4, R5, R8a and R8b are as defined for compounds of formula (I), may be prepared from a compound of formula (I), wherein m is 0, n is 0 and Z is C(O)OR10, by treatment with trimethylsilylchlorosulfonate in a suitable solvent at a suitable temperature, as described in reaction scheme 4. Preferred conditions include heating the carboxylate precursor in neat trimethylsilylchlorosulfonate at a temperature between 25° C. and 150° C.
Furthermore, compounds of formula (I) may be prepared by reacting compounds of formula (X), wherein R3, R4, R5, R8a and R8b are as defined for compounds of formula (I), with a suitable alcohol of formula (WW), wherein R1, R2, Q, X, n and Z are as defined for compounds of formula (I), under Mitsunobu-type conditions such as those reported by Petit et al, Tet. Lett. 2008, 49 (22), 3663, as described in reaction scheme 5. Suitable phosphines include triphenylphosphine, suitable azodicarboxylates include diisopropylazodicarboxylate and suitable acids include fluoroboric acid, triflic acid and bis(trifluoromethylsulfonyl)amine. Alcohols of formula (WW) are either known in the literature or may be prepared by known literature methods or may be commercially available.
Compounds of formula (I) may also be prepared by reacting compounds of formula (C), wherein R3, R4, R5, R8a and R8b are as defined for compounds of formula (I) and R′ is H, C1-C4alkyl or C1-C4alkylcarbonyl, with a hydrazine of formula (D), wherein R1, R2, Q, X, n and Z are as defined for compounds of formula (I), in a suitable solvent or mixture of solvents, in the presence of a suitable acid at a suitable temperature, between −78° C. and 150° C., as described in reaction scheme 6. Suitable solvents, or mixtures thereof, include, but are not limited to, alcohols, such as methanol, ethanol and isopropanol, water, aqueous hydrochloric acid, aqueous sulfuric acid, acetic acid and trifluoroacetic acid. Hydrazine compounds of formula (D), for example 2,2-dimethylpropyl 2-hydrazinoethanesulfonate or ethyl 3-hydrazinopropanoate, are either known in the literature or may be prepared by known literature procedures.
Compounds of formula (C) may be prepared by reacting compounds of formula (G), wherein R3, R4, R5, R8a and R8b are as defined for compounds of formula (I), with an oxidising agent in a suitable solvent at a suitable temperature, between −78° C. and 150° C., optionally in the presence of a suitable base, as described in reaction scheme 7. Suitable oxidising agents include, but are not limited to, bromine and suitable solvents include, but are not limited to alcohols such as methanol, ethanol and isopropanol. Suitable bases include, but are not limited to, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate and potassium acetate. Similar reactions are known in the literature (for example Hufford, D. L.; Tarbell, D. S.; Koszalka, T. R. J. Amer. Chem. Soc., 1952, 3014). Furans of formula (G) are known in the literature or may be prepared using literature methods.
Compounds of formula (X) may be prepared by classical amide bond forming reactions which are very well known in the literature. Examples include, but are not limited to, reacting an amine of formula (K), wherein R8a and R8b are as previously defined, with an acid halide of formula (J), wherein T is halogen and R3, R4 and R5 are as previously defined, in a suitable solvent or mixture of solvents, optionally in the presence of a suitable base at a suitable temperature between −78° C. and 200° C.
In an alternative approach a compound of formula (X) may be prepared by reacting an amine of formula (K) with an ester or activated ester of formula (J), wherein T is, for example, —OC1-C6alkyl, pentafluorophenol, p-nitrophenol, 2,4,6-trichlorophenol, —OC(O)R′″ or —OS(O)2R′″, and R′″ is, for example, C1-C6alkyl, C1-C6haloalkyl or optionally substituted phenyl. Such reactions are performed in a suitable solvent or mixture of solvents and optionally in the presence of a suitable base at a suitable temperature between −78° C. and 200° C. Suitable bases include, but are not limited to, triethylamine, pyridine, N,N-diisopropylethylamine, an alkali metal carbonate, such as sodium carbonate, potassium carbonate or cesium carbonate, or an alkali metal alkoxide, such as sodium methoxide. Suitable solvents include, but are not limited to, dichloromethane, N,N-dimethylformamide, THF or toluene. These reactions are described in scheme 8. Compounds of formula (J) and of formula (K) are either known in the literature or may be prepared by known literature methods or may be commercially available.
In a further approach compounds of formula (X) may be prepared from an amine of formula (K), as previously described, and a carboxylic acid of formula (L), wherein R3, R4 and R5 are as defined for compounds of formula (I), in the presence of a suitable coupling agent in a suitable solvent or mixture of solvents, at a suitable temperature between −78° C. and 200° C., and optionally in the presence of a suitable base. Suitable coupling reagents include, but are not limited to, a carbodiimide, for example dicyclohexylcarbodiimide or 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride, a phosphonic anhydride, for example 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide, or a phosphonium salt, for example benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphonium hexafluorophosphate. Suitable solvents include, but are not limited to, dichloromethane, N,N-dimethylformamide, THF or toluene, and suitable bases include, but are not limited to, triethylamine, pyridine and N,N-diisopropylethylamine. This reaction is described in scheme 9. Compounds of formula (L) are either known in the literature or may be prepared by known literature methods or may be commercially available.
Compounds of formula (X), as previously defined, may be prepared from compounds of formula (P) and formula (O), in a suitable solvent, at a suitable temperature, as outlined in reaction scheme 10. Examples of such a reaction are known in the literature, for example, WO 2001038332. Compounds of formula (P) and of formula (O) are known in the literature, or may be prepared by known methods.
Compounds of formula (X), as previously defined, may also be prepared by the aminocarbonylation of a compound of formula (ZZ), wherein Hal is defined as a halogen or pseudo halogen, for example triflate, mesylate and tosylate. Example conditions include, but are not limited to, reacting a compound of formula (ZZ) with an amine of formula (K) and carbon monoxide, in the presence of a suitable transition metal, suitable base, in a suitable solvent at a suitable temperature and pressure. Such reactions are known in the literature, for example Wang, J. Y., Strom, A. E., Hartwig, J. F., J. Am. Chem. Soc. 2018, 140, 7979.
In an approach outlined in reaction scheme 12, a compound of formula (X), wherein R8a and R8b are as previously defined, may be prepared from a compound of formula (Q), wherein W is a functional group which can be converted through one or more chemical steps into an amide. Such functional groups include, but are not limited to, nitrile, halogen, aldehyde and oxime. These functional group transformations to an amide are well known in the literature. Compounds of formula (Q) are either known in the literature or can be prepared by known methods.
The compounds according to the invention can be used as herbicidal agents in unmodified form, but they are generally formulated into compositions in various ways using formulation adjuvants, such as carriers, solvents and surface-active substances. The formulations can be in various physical forms, e.g. in the form of dusting powders, gels, wettable powders, water-dispersible granules, water-dispersible tablets, effervescent pellets, emulsifiable concentrates, microemulsifiable concentrates, oil-in-water emulsions, oil-flowables, aqueous dispersions, oily dispersions, suspo-emulsions, capsule suspensions, emulsifiable granules, soluble liquids, water-soluble concentrates (with water or a water-miscible organic solvent as carrier), impregnated polymer films or in other forms known e.g. from the Manual on Development and Use of FAO and WHO Specifications for Pesticides, United Nations, First Edition, Second Revision (2010). Such formulations can either be used directly or diluted prior to use. The dilutions can be made, for example, with water, liquid fertilisers, micronutrients, biological organisms, oil or solvents.
The formulations can be prepared e.g. by mixing the active ingredient with the formulation adjuvants in order to obtain compositions in the form of finely divided solids, granules, solutions, dispersions or emulsions. The active ingredients can also be formulated with other adjuvants, such as finely divided solids, mineral oils, oils of vegetable or animal origin, modified oils of vegetable or animal origin, organic solvents, water, surface-active substances or combinations thereof.
The active ingredients can also be contained in very fine microcapsules. Microcapsules contain the active ingredients in a porous carrier. This enables the active ingredients to be released into the environment in controlled amounts (e.g. slow-release). Microcapsules usually have a diameter of from 0.1 to 500 microns. They contain active ingredients in an amount of about from 25 to 95% by weight of the capsule weight. The active ingredients can be in the form of a monolithic solid, in the form of fine particles in solid or liquid dispersion or in the form of a suitable solution. The encapsulating membranes can comprise, for example, natural or synthetic rubbers, cellulose, styrene/butadiene copolymers, polyacrylonitrile, polyacrylate, polyesters, polyamides, polyureas, polyurethane or chemically modified polymers and starch xanthates or other polymers that are known to the person skilled in the art. Alternatively, very fine microcapsules can be formed in which the active ingredient is contained in the form of finely divided particles in a solid matrix of base substance, but the microcapsules are not themselves encapsulated.
The formulation adjuvants that are suitable for the preparation of the compositions according to the invention are known per se. As liquid carriers there may be used: water, toluene, xylene, petroleum ether, vegetable oils, acetone, methyl ethyl ketone, cyclohexanone, acid anhydrides, acetonitrile, acetophenone, amyl acetate, 2-butanone, butylene carbonate, chlorobenzene, cyclohexane, cyclohexanol, alkyl esters of acetic acid, diacetone alcohol, 1,2-dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, N,N-dimethylformamide, dimethyl sulfoxide, 1,4-dioxane, dipropylene glycol, dipropylene glycol methyl ether, dipropylene glycol dibenzoate, diproxitol, alkylpyrrolidone, ethyl acetate, 2-ethylhexanol, ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, alpha-pinene, d-limonene, ethyl lactate, ethylene glycol, ethylene glycol butyl ether, ethylene glycol methyl ether, gamma-butyrolactone, glycerol, glycerol acetate, glycerol diacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropylbenzene, isopropyl myristate, lactic acid, laurylamine, mesityl oxide, methoxypropanol, methyl isoamyl ketone, methyl isobutyl ketone, methyl laurate, methyl octanoate, methyl oleate, methylene chloride, m-xylene, n-hexane, n-octylamine, octadecanoic acid, octylamine acetate, oleic acid, oleylamine, o-xylene, phenol, polyethylene glycol, propionic acid, propyl lactate, propylene carbonate, propylene glycol, propylene glycol methyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylenesulfonic acid, paraffin, mineral oil, trichloroethylene, perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, propylene glycol methyl ether, diethylene glycol methyl ether, methanol, ethanol, isopropanol, and alcohols of higher molecular weight, such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, ethylene glycol, propylene glycol, glycerol, N-methyl-2-pyrrolidone and the like.
Suitable solid carriers are, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, kieselguhr, limestone, calcium carbonate, bentonite, calcium montmorillonite, cottonseed husks, wheat flour, soybean flour, pumice, wood flour, ground walnut shells, lignin and similar substances.
A large number of surface-active substances can advantageously be used in both solid and liquid formulations, especially in those formulations which can be diluted with a carrier prior to use. Surface-active substances may be anionic, cationic, non-ionic or polymeric and they can be used as emulsifiers, wetting agents or suspending agents or for other purposes. Typical surface-active substances include, for example, salts of alkyl sulfates, such as diethanolammonium lauryl sulfate; salts of alkylarylsulfonates, such as calcium dodecylbenzenesulfonate; alkylphenol/alkylene oxide addition products, such as nonylphenol ethoxylate; alcohol/alkylene oxide addition products, such as tridecylalcohol ethoxylate; soaps, such as sodium stearate; salts of alkylnaphthalenesulfonates, such as sodium dibutylnaphthalenesulfonate; dialkyl esters of sulfosuccinate salts, such as sodium di(2-ethylhexyl)sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary amines, such as lauryltrimethylammonium chloride, polyethylene glycol esters of fatty acids, such as polyethylene glycol stearate; block copolymers of ethylene oxide and propylene oxide; and salts of mono- and di-alkylphosphate esters; and also further substances described e.g. in McCutcheon's Detergents and Emulsifiers Annual, MC Publishing Corp., Ridgewood N.J. (1981).
Further adjuvants that can be used in pesticidal formulations include crystallisation inhibitors, viscosity modifiers, suspending agents, dyes, anti-oxidants, foaming agents, light absorbers, mixing auxiliaries, antifoams, complexing agents, neutralising or pH-modifying substances and buffers, corrosion inhibitors, fragrances, wetting agents, take-up enhancers, micronutrients, plasticisers, glidants, lubricants, dispersants, thickeners, antifreezes, microbicides, and liquid and solid fertilisers.
The compositions according to the invention can include an additive comprising an oil of vegetable or animal origin, a mineral oil, alkyl esters of such oils or mixtures of such oils and oil derivatives. The amount of oil additive in the composition according to the invention is generally from 0.01 to 10%, based on the mixture to be applied. For example, the oil additive can be added to a spray tank in the desired concentration after a spray mixture has been prepared. Preferred oil additives comprise mineral oils or an oil of vegetable origin, for example rapeseed oil, olive oil or sunflower oil, emulsified vegetable oil, alkyl esters of oils of vegetable origin, for example the methyl derivatives, or an oil of animal origin, such as fish oil or beef tallow. Preferred oil additives comprise alkyl esters of C8-C22 fatty acids, especially the methyl derivatives of C12-C18 fatty acids, for example the methyl esters of lauric acid, palmitic acid and oleic acid (methyl laurate, methyl palmitate and methyl oleate, respectively). Many oil derivatives are known from the Compendium of Herbicide Adjuvants, 10th Edition, Southern Illinois University, 2010.
The herbicidal compositions generally comprise from 0.1 to 99% by weight, especially from 0.1 to 95% by weight, compounds of formula (I) and from 1 to 99.9% by weight of a formulation adjuvant which preferably includes from 0 to 25% by weight of a surface-active substance. The inventive compositions generally comprise from 0.1 to 99% by weight, especially from 0.1 to 95% by weight, of compounds of the present invention and from 1 to 99.9% by weight of a formulation adjuvant which preferably includes from 0 to 25% by weight of a surface-active substance. Whereas commercial products may preferably be formulated as concentrates, the end user will normally employ dilute formulations.
The rates of application vary within wide limits and depend on the nature of the soil, the method of application, the crop plant, the pest to be controlled, the prevailing climatic conditions, and other factors governed by the method of application, the time of application and the target crop. As a general guideline compounds may be applied at a rate of from 1 to 2000 I/ha, especially from 10 to 1000 I/ha.
Preferred formulations can have the following compositions (weight %):
active ingredient: 1 to 95%, preferably 60 to 90%
surface-active agent: 1 to 30%, preferably 5 to 20%
liquid carrier: 1 to 80%, preferably 1 to 35%
active ingredient: 0.1 to 10%, preferably 0.1 to 5%
solid carrier: 99.9 to 90%, preferably 99.9 to 99%
Suspension concentrates:
active ingredient: 5 to 75%.,preferably 10 to 50%
water: 94 to 24%, preferably 88 to 30%
surface-active agent: 1 to 40%, preferably 2 to 30%
Wettable powders:
active ingredient: 0.5 to 90%, preferably 1 to 80%
surface-active agent: 0.5 to 20%, preferably 1 to 15%
solid carrier: 5 to 95%, preferably 15 to 90%
active ingredient: 0.1to 30%, preferably 0.1 to 15%
solid carrier: 99.5to 70%, preferably 97 to 85%
The composition of the present may further comprise at least one additional pesticide. For example, the compounds according to the invention can also be used in combination with other herbicides or plant growth regulators. In a preferred embodiment the additional pesticide is a herbicide and/or herbicide safener.
Thus, compounds of formula (I) can be used in combination with one or more other herbicides to provide various herbicidal mixtures. Specific examples of such mixtures include (wherein “I” represents a compound of formula (I)):—I+acetochlor, I+acifluorfen (including acifluorfen-sodium), I+aclonifen, I+ametryn, I+amicarbazone, I+aminopyralid, I+aminotriazole, I+atrazine, I+beflubutamid-M, I+bensulfuron (including bensulfuron-methyl), I+bentazone, I+bicyclopyrone, I+bilanafos, I+bispyribac-sodium, I+bixlozone, I+bromacil, I+bromoxynil, I+butachlor, I+butafenacil, I+carfentrazone (including carfentrazone-ethyl), I+cloransulam (including cloransulam-methyl), I+chlorimuron (including chlorimuron-ethyl), I+chlorotoluron, I+chlorsulfuron, I+cinmethylin, I+clacyfos, I+clethodim, I+clodinafop (including clodinafop-propargyl), I+clomazone, I+clopyralid, I+cyclopyranil, I+cyclopyrimorate, I+cyclosulfamuron, I+cyhalofop (including cyhalofop-butyl), I+2,4-D (including the choline salt and 2-ethylhexyl ester thereof), I+2,4-DB, I+desmedipham, I+dicamba (including the aluminium, aminopropyl, bis-aminopropylmethyl, choline, dichloroprop, diglycolamine, dimethylamine, dimethylammonium, potassium and sodium salts thereof) I+diclosulam, I+diflufenican, I+diflufenzopyr, I+dimethachlor, I+dimethenamid-P, I+diquat dibromide, diuron, I+ethalfluralin, I+ethofumesate, I+fenoxaprop (including fenoxaprop-P-ethyl), I+fenoxasulfone, I+fenquinotrione, I+fentrazamide, I+flazasulfuron, I+florasulam, I+florpyrauxifen (including florpyrauxifen-benzyl), I+fluazifop (including fluazifop-P-butyl), I+flucarbazone (including flucarbazone-sodium), I+flufenacet, I+flumetsulam, I+flumioxazin, I+fluometuron, I+flupyrsulfuron (including flupyrsulfuron-methyl-sodium), I+fluroxypyr (including fluroxypyr-meptyl), I+fomesafen, I+foramsulfuron, I+glufosinate (including the ammonium salt thereof), I+glyphosate (including the diammonium, isopropylammonium and potassium salts thereof), I+halauxifen (including halauxifen-methyl), I+haloxyfop (including haloxyfop-methyl), I+hexazinone, I+hydantocidin, I+imazamox, I+imazapic, I+imazapyr, I+imazethapyr, I+indaziflam, I+iodosulfuron (including iodosulfuron-methyl-sodium), I+iofensulfuron (including iofensulfuron-sodium), I+ioxynil, I+isoproturon, I+isoxaflutole, I+lancotrione, I+MCPA, I+MCPB, I+mecoprop-P, I+mesosulfuron (including mesosulfuron-methyl), I+mesotrione, I+metamitron, I+metazachlor, I+methiozolin, I+metolachlor, I+metosulam, I+metribuzin, I+metsulfuron, I+napropamide, I+nicosulfuron, I+norflurazon, I+oxadiazon, I+oxasulfuron, I+oxyfluorfen, I+paraquat dichloride, I+pendimethalin, I+penoxsulam, I+phenmedipham, I+picloram, I+pinoxaden, I+pretilachlor, I+primisulfuron-methyl, I+prometryne, I+propanil, I+propaquizafop, I+propyrisulfuron, I+propyzamide, I+prosulfocarb, I+prosulfuron, I+pyraclonil, I+pyraflufen (including pyraflufen-ethyl), I+pyrasulfotole, I+pyridate, I+pyriftalid, I+pyrimisulfan, I+pyroxasulfone, I+pyroxsulam, I+quinclorac, I+quinmerac, I+quizalofop (including quizalofop-P-ethyl and quizalofop-P-tefuryl), I+rimsulfuron, I+saflufenacil, I+sethoxydim, I+simazine, I+S-metalochlor, I+sulfentrazone, I+sulfosulfuron, I+tebuthiuron, I+tefuryltrione, I+tembotrione, I+terbuthylazine, I+terbutryn, I+tetflupyrolimet, I+thiencarbazone, I+thifensulfuron, I+tiafenacil, I+tolpyralate, I+topramezone, I+tralkoxydim, I+triafamone, I+triallate, I+triasulfuron, I+tribenuron (including tribenuron-methyl), I+triclopyr, I+trifloxysulfuron (including trifloxysulfuron-sodium), I+trifludimoxazin, I+trifluralin, I+triflusulfuron, I+ethyl 2-[[3-[2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimid in-1-yl]phenoxy]-2-pyridyl]oxy]acetate, I+3-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydropyrimidin-1(2H)-yl)phenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid ethyl ester, I+4-hydroxy-1-methoxy-5-methyl-3-[4-(trifluoromethyl)-2-pyridyl]imidazolidin-2-one, I+4-hydroxy-1,5-dimethyl-3-[4-(trifluoromethyl)-2-pyridyl]imidazolidin-2-one, I+5-ethoxy-4-hydroxy-1-methyl-3-[4-(trifluoromethyl)-2-pyridyl]imidazolidin-2-one, I+4-hydroxy-1-methyl-3-[4-(trifluoromethyl)-2-pyridyl]imidazolidin-2-one, I+4-hydroxy-1,5-dimethyl-3-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]imidazolid in-2-one, I+(4R)1-(5-tert-butylisoxazol-3-yl)-4-ethoxy-5-hydroxy-3-methyl-imidazolidin-2-one, I+3-[2-(3,4-d methoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]bicyclo[3.2.1]octane-2,4-dione, I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-5-methyl-cyclohexane-1,3-dione, I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]cyclohexane-1,3-dione, I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-5,5-dimethyl-cyclohexane-1,3-dione, I+6-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-2,2,4,4-tetramethyl-cyclohexane-1,3,5-trione, I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-5-ethyl-cyclohexane-1,3-dione, I+2-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-4,4,6,6-tetramethyl-cyclohexane-1,3-dione, I+2-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]-5-methyl-cyclohexane-1,3-dione, I+3-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]bicyclo[3.2.1]octane-2,4-dione, I+2-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]-5,5-dimethyl-cyclohexane-1,3-dione, I+6-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]-2,2,4,4-tetramethyl-cyclohexane-1,3,5-trione, I+2-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]cyclohexane-1,3-dione, I+4-[2-(3,4-dimethoxyphenyl)-6-methyl-3-oxo-pyridazine-4-carbonyl]-2,2,6,6-tetramethyl-tetrahydropyran-3,5-dione, I+4-[6-cyclopropyl-2-(3,4-dimethoxyphenyl)-3-oxo-pyridazine-4-carbonyl]-2,2,6,6-tetramethyl-tetrahydropyran-3,5-dione, I+4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6-yl)pyridine-2-carboxylic acid (including agrochemically acceptable esters thereof, for example, methyl 4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6-yl)pyridine-2-carboxylate).
The mixing partners of the compound of formula (I) may also be in the form of esters or salts, as mentioned e.g. in The Pesticide Manual, Fourteenth Edition, British Crop Protection Council, 2006.
The compound of formula (I) can also be used in mixtures with other agrochemicals such as fungicides, nematicides or insecticides, examples of which are given in The Pesticide Manual.
The mixing ratio of the compound of formula (I) to the mixing partner is preferably from 1:100 to 1000:1.
The mixtures can advantageously be used in the above-mentioned formulations (in which case “active ingredient” relates to the respective mixture of compound of formula (I) with the mixing partner).
Compounds of formula (I) of the present invention may also be combined with herbicide safeners. Preferred combinations (wherein “I” represents a compound of formula (I)) include:—I+benoxacor: I+cloquintocet (including cloquintocet-mexyl); I+cyprosulfamide; I+dichlormid; I+fenchlorazole (including fenchlorazole-ethyl); I+fenclorim; I+fluxofenim; I+furilazole I+isoxadifen (including isoxadifen-ethyl); I+mefenpyr (including mefenpyr-diethyl); I+metcamifen; and I+oxabetrinil.
Particularly preferred are mixtures of a compound of formula (I) with cyprosulfamide, isoxadifen (including isoxadifen-ethyl), cloquintocet (including cloquintocet-mexyl) and/or N-(2-methoxybenzoyl)-4-[(methyl-aminocarbonyl)amino]benzenesulfonamide.
The safeners of the compound of formula (I) may also be in the form of esters or salts, as mentioned e.g. in The Pesticide Manual, 14th Edition (BCPC), 2006. The reference to cloquintocet-mexyl also applies to a lithium, sodium, potassium, calcium, magnesium, aluminium, iron, ammonium, quaternary ammonium, sulfonium or phosphonium salt thereof as disclosed in WO 02/34048, and the reference to fenchlorazole-ethyl also applies to fenchlorazole, etc.
Preferably the mixing ratio of compound of formula (I) to safener is from 100:1 to 1:10, especially from 20:1 to 1:1.
The mixtures can advantageously be used in the above-mentioned formulations (in which case “active ingredient” relates to the respective mixture of compound of formula (I) with the safener).
The compounds of formula (I) of this invention are useful as herbicides. The present invention therefore further comprises a method for controlling unwanted plants comprising applying to the said plants or a locus comprising them, an effective amount of a compound of the invention or a herbicidal composition containing said compound. ‘Controlling’ means killing, reducing or retarding growth or preventing or reducing germination. Generally the plants to be controlled are unwanted plants (weeds). ‘Locus’ means the area in which the plants are growing or will grow.
The rates of application of compounds of formula (I) may vary within wide limits and depend on the nature of the soil, the method of application (pre-emergence; post-emergence; application to the seed furrow; no tillage application etc.), the crop plant, the weed(s) to be controlled, the prevailing climatic conditions, and other factors governed by the method of application, the time of application and the target crop. The compounds of formula (I) according to the invention are generally applied at a rate of from 10 to 2000 g/ha, especially from 50 to 1000 g/ha.
The application is generally made by spraying the composition, typically by tractor mounted sprayer for large areas, but other methods such as dusting (for powders), drip or drench can also be used.
Useful plants in which the composition according to the invention can be used include crops such as cereals, for example barley and wheat, cotton, oilseed rape, sunflower, maize, rice, soybeans, sugar beet, sugar cane and turf.
Crop plants can also include trees, such as fruit trees, palm trees, coconut trees or other nuts. Also included are vines such as grapes, fruit bushes, fruit plants and vegetables.
Crops are to be understood as also including those crops which have been rendered tolerant to herbicides or classes of herbicides (e.g. ALS-, GS-, EPSPS-, PPO-, ACCase- and HPPD-inhibitors) by conventional methods of breeding or by genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding is Clearfield® summer rape (canola). Examples of crops that have been rendered tolerant to herbicides by genetic engineering methods include e.g. glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® and LibertyLink®.
Crops are also to be understood as being those which have been rendered resistant to harmful insects by genetic engineering methods, for example Bt maize (resistant to European corn borer), Bt cotton (resistant to cotton boll weevil) and also Bt potatoes (resistant to Colorado beetle). Examples of Bt maize are the Bt 176 maize hybrids of NK® (Syngenta Seeds). The Bt toxin is a protein that is formed naturally by Bacillus thuringiensis soil bacteria. Examples of toxins, or transgenic plants able to synthesise such toxins, are described in EP-A-451 878, EP-A-374 753, WO 93/07278, WO 95/34656, WO 03/052073 and EP-A-427 529. Examples of transgenic plants comprising one or more genes that code for an insecticidal resistance and express one or more toxins are KnockOut® (maize), Yield Gard® (maize), NuCOTIN33B® (cotton), Bollgard® (cotton), NewLeaf® (potatoes), NatureGard® and Protexcta®.
Plant crops or seed material thereof can be both resistant to herbicides and, at the same time, resistant to insect feeding (“stacked” transgenic events). For example, seed can have the ability to express an insecticidal Cry3 protein while at the same time being tolerant to glyphosate.
Crops are also to be understood to include those which are obtained by conventional methods of breeding or genetic engineering and contain so-called output traits (e.g. improved storage stability, higher nutritional value and improved flavour).
Other useful plants include turf grass for example in golf-courses, lawns, parks and roadsides, or grown commercially for sod, and ornamental plants such as flowers or bushes.
Compounds of formula (I) and compositions of the invention can typically be used to control a wide variety of monocotyledonous and dicotyledonous weed species. Examples of monocotyledonous species that can typically be controlled include Alopecurus myosuroides, Avena fatua, Brachiaria plantaginea, Bromus tectorum, Cyperus esculentus, Digitaria sanguinalis, Echinochloa crus-galli, Lolium perenne, Lolium multiflorum, Panicum miliaceum, Poa annus, Setaria viridis, Setaria faberi and Sorghum bicolor. Examples of dicotyledonous species that can be controlled include Abutilon theophrasti, Amaranthus retroflexus, Bidens pilosa, Chenopodium album, Euphorbia heterophylla, Galium aparine, Ipomoea hederacea, Kochia scoparia, Polygonum convolvulus, Sida spinosa, Sinapis arvensis, Solanum nigrum, Stellaria media, Veronica persica and Xanthium strumarium.
The compounds of formula (I) are also useful for pre-harvest desiccation in crops, for example, but not limited to, potatoes, soybean, sunflowers and cotton. Pre-harvest desiccation is used to desiccate crop foliage without significant damage to the crop itself to aid harvesting.
Compounds/compositions of the invention are particularly useful in non-selective burn-down applications, and as such may also be used to control volunteer or escape crop plants.
Various aspects and embodiments of the present invention will now be illustrated in more detail by way of example. It will be appreciated that modification of detail may be made without departing from the scope of the invention.
The Examples which follow serve to illustrate, but do not limit, the invention.
The combination is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording wettable powders that can be diluted with water to give suspensions of the desired concentration.
Emulsions of any required dilution, which can be used in plant protection, can be obtained from this concentrate by dilution with water.
Ready-for-use dusts are obtained by mixing the combination with the carrier and grinding the mixture in a suitable mill.
The combination is mixed and ground with the adjuvants, and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air.
The finely ground combination is uniformly applied, in a mixer, to the kaolin moistened with polyethylene glycol. Non-dusty coated granules are obtained in this manner.
The finely ground combination is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water.
28 parts of the combination are mixed with 2 parts of an aromatic solvent and 7 parts of toluene diisocyanate/polymethylene-polyphenylisocyanate-mixture (8:1). This mixture is emulsified in a mixture of 1.2 parts of polyvinylalcohol, 0.05 parts of a defoamer and 51.6 parts of water until the desired particle size is achieved. To this emulsion a mixture of 2.8 parts 1,6-diaminohexane in 5.3 parts of water is added. The mixture is agitated until the polymerization reaction is completed.
The obtained capsule suspension is stabilized by adding 0.25 parts of a thickener and 3 parts of a dispersing agent. The capsule suspension formulation contains 28% of the active ingredients. The medium capsule diameter is 8-15 microns.
The resulting formulation is applied to seeds as an aqueous suspension in an apparatus suitable for that purpose.
Boc=tert-butyloxycarbonyl
br=broad
CDCl3=chloroform-d
CD3OD=methanol-d
° C.=degrees Celsius
D2O=water-d
DCM=dichloromethane
d=doublet
dd=double doublet
dt=double triplet
DMSO=dimethylsulfoxide
EtOAc=ethyl acetate
h=hour(s)
HCl=hydrochloric acid
HPLC=high-performance liquid chromatography (description of the apparatus and the
methods used for HPLC are given below)
m=multiplet
M=molar
min=minutes
MHz=mega hertz
mL=millilitre
mp=melting point
ppm=parts per million
q=quartet
quin=quintet
rt=room temperature
s=singlet
=triplet
THF=tetrahydrofuran
Compounds purified by mass directed preparative HPLC using ES+/ES− on a Waters FractionLynx Autopurification system comprising a 2767 injector/collector with a 2545 gradient pump, two 515 isocratic pumps, SFO, 2998 photodiode array (Wavelength range (nm): 210 to 400), 2424 ELSD and QDa mass spectrometer. A Waters Atlantis T3 5 micron 19×10 mm guard column was used with a Waters Atlantis T3 OBD, 5 micron 30×100 mm prep column.
Ionisation method: Electrospray positive and negative: Cone (V) 20.00, Source Temperature (° C.) 120, Cone Gas Flow (L/Hr.) 50
Mass range (Da): positive 100 to 800, negative 115 to 800.
The preparative HPLC was conducted using an 11.4 minute run time (not using at column dilution, bypassed with the column selector), according to the following gradient table:
515 pump 0 ml/min Acetonitrile (ACD)
515 pump 1 ml/min 90% Methanol/10% Water (make up pump)
Solvent A: Water with 0.05% Trifluoroacetic Acid
Solvent B: Acetonitrile with 0.05% Trifluoroacetic Acid
Additional compounds in Table A (below) were prepared by analogues procedures, from appropriate starting materials. The skilled person would understand that the compounds of formula (I) may exist as an agronomically acceptable salt, a zwitterion or an agronomically acceptable salt of a zwitterion as described hereinbefore. Where mentioned the specific counterion is not considered to be limiting, and the compound of formula (I) may be formed with any suitable counter ion.
NMR spectra contained herein were recorded on either a 400 MHz Bruker AVANCE III HD equipped with a Bruker SMART probe unless otherwise stated. Chemical shifts are expressed as ppm downfield from TMS, with an internal reference of either TMS or the residual solvent signals. The following multiplicities are used to describe the peaks: s=singlet, d=doublet, t=triplet, dd=double doublet, dt=double triplet, q=quartet, quin=quintet, m=multiplet. Additionally br. is used to describe a broad signal and app. is used to describe and apparent multiplicity.
To a solution of pyridazine-4-carboxylic acid (200 mg) in methanol (2 mL) at 0° C. under a nitrogen atmosphere was added thionyl chloride (0.49 mL) drop wise. The reaction mixture was stirred at 65° C. for 2 hours. The reaction mixture was concentrated and partitioned between ethyl acetate (100 mL) and saturated aqueous sodium bicarbonate solution (50 mL). The aqueous was extracted with further ethyl acetate (2×100 mL). The combined organic layers were concentrated to afford methyl pyridazine-4-carboxylate as a pale brown solid.
1H NMR (400 MHz, DMSO-d6) 9.58-9.60 (m, 1H) 9.51-9.53 (m, 1H) 8.11 (dd, 1H) 3.93 (s, 3H)
A mixture of pyridazine-4-carboxylate (50 mg) in methylamine solution (2M in methanol, 1 mL) was heated at 100° C. for 2 hours in a sealed vessel. The reaction mixture was cooled, concentrated and purified by chromatography on silica eluting with 80% ethyl acetate in hexanes to give N-methylpyridazine-4-carboxamide as a brown solid.
1H NMR (400 MHz, DMSO-d6) 9.51-9.53 (m, 1H) 9.41-9.43 (m, 1H) 8.97 (brs, 1H) 7.96-7.98 (m, 1H) 2.83 (d, 3H)
To a mixture of N-methylpyridazine-4-carboxamide (200 mg) in water (4 mL) was added sodium 2-bromoethanesulfonate (0.461 g). The mixture was heated at 100° C. for 30 hours. The reaction mixture was concentrated and triturated with methyl tert-butyl ether to afford a crude solid. This crude solid was purified by preparative reverse phase HPLC to give 2-[4-(methylcarbamoyl)pyridazin-1-ium-1-yl]ethanesulfonate as white solid.
1H NMR (400 MHz, D2O) 9.88 (d, 1H), 9.68 (d, 1H), 8.74 (d, 1H), 5.20-5.25 (m, 2H), 3.55-3.66 (m, 2H), 2.91 (s, 3H) (NH proton missing)
To a mixture of N-methylpyridazine-4-carboxamide (200 mg) in water (4 mL) was added 3-bromopropanoic acid (0.401 g). The mixture was heated at 110° C. for 18 hours, then cooled and concentrated. The crude product was washed with methyl tert-butyl ether and the resulting crude product was purified by preparative reverse phase HPLC to afford 3-[4-(methylcarbamoyl)pyridazin-1-ium-1-yl]propanoic acid trifluoroacetate as white solid.
1H NMR (400 MHz, D2O) 9.94 (d, 1H), 9.72 (d, 1H), 8.80 (dd, 1H), 5.16 (t, 2H), 3.25 (t, 2H), 2.98 (s, 3H) (NH and CO2H protons missing)
To a solution of 3-methylpyridazine-4-carboxylic acid (500 mg) in dichloromethane (5 mL), at room temperature under a nitrogen atmosphere, was added 4-dimethylaminopyridine (89 mg) and pentafluorophenol (0.37 mL) drop wise. The reaction mixture was stirred at room temperature for 16 hours, then quenched with ice cold water (50 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were concentrated to afford (2,3,4,5,6-pentafluorophenyl) 3-methylpyridazine-4-carboxylate as a pale white solid, which was used without further purification.
A mixture of (2,3,4,5,6-pentafluorophenyl) 3-methylpyridazine-4-carboxylate (800 mg) and methylamine solution (4M in THF, 3.3 mL), under a nitrogen atmosphere, was heated at 80° C. for 16 hours. The reaction mixture was cooled, concentrated and purified by chromatography on silica eluting with 45% ethyl acetate in hexanes to afford N,3-dimethylpyridazine-4-carboxamide as a brown oil.
1H NMR (400 MHz, DMSO-d6) 9.19 (d, 1H) 8.72 (br s, 1H) 7.57 (d, 1H) 2.79 (d, 3H) 2.65 (s, 3H)
To a solution of N,3-dimethylpyridazine-4-carboxamide (300 mg) in acetonitrile (6 mL) was added ethyl 3-bromopropanoate (0.381 mL). The mixture was heated at 90° C. for 16 hours, then cooled and concentrated. The crude product was triturated with methyl tert-butyl ether to afford crude ethyl 3-[3-methyl-4-(methylcarbamoyl)pyridazin-1-ium-1-yl]propanoate bromide as yellow gum which was used without further purification in the next step.
A solution of crude ethyl 3-[3-methyl-4-(methylcarbamoyl)pyridazin-1-ium-1-yl]propanoate bromide (0.3 g) in 2M aqueous hydrochloric acid (10 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated and purified by preparative reverse phase HPLC (trifluoroacetic acid is present in the eluent) to afford 3-[3-methyl-4-(methylcarbamoyl)pyridazin-1-ium-1-yl]propanoic acid 2,2,2-trifluoroacetate.
1H NMR (400 MHz, D2O) 9.68 (d, 1H) 8.42 (d, 1H) 5.01 (t, 2H), 3.18 (t, 2H), 2.90 (s, 3H), 2.73 (s, 3H) (NH and CO2H protons missing)
To a solution of pyridazine-4-carboxylic acid (1.5 g) in N,N-dimethylformamide (30 mL) at room temperature under a nitrogen atmosphere was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (5.20 g) followed by N,N-diisopropylethylamine (9.4 g) drop wise. After 30 minutes stirring N-methylaniline (1.9 g) was added and stirring was continued for a further 16 hours. The reaction mixture was quenched with water (50 mL) and extracted with ethyl acetate (3×100 mL). The organic phases were combined, washed with saturated aqueous lithium chloride (2×100 ml) and concentrated. The crude product was purified by chromatography on silica eluting with 45% ethyl acetate in hexanes to afford N-methyl-N-phenyl-pyridazine-4-carboxamide as a brown oil.
1H NMR (400 MHz, DMSO-d6) 9.13 (br d, 1H) 9.08-8.95 (m, 1H) 7.48 (br s, 1H) 7.35-7.20 (m, 5H) 2.68 (s, 3H)
To a solution of N-methyl-N-phenyl-pyridazine-4-carboxamide (800 mg) in acetonitrile (16 mL) was added methyl 3-bromopropanoate (0.939 g). The mixture was heated at 90° C. for 18 hours, then concentrated and washed with tert-butyl methyl ether to give crude methyl 3-[4-[methyl(phenyl)carbamoyl]pyridazin-1-ium-1-yl]propanoate bromide as yellow gum which was used without further purification.
A solution of crude methyl 3-[4-[methyl(phenyl)carbamoyl]pyridazin-1-ium-1-yl]propanoate bromide (0.6 g) in 2M aqueous hydrochloric acid (10 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated and purified by preparative reverse phase HPLC (trifluoroacetic acid is present in the eluent) to afford 3-[4-[methyl(phenyl)carbamoyl]pyridazin-1-ium-1-yl]propanoic acid trifluoroacetate as a solid.
1H NMR (400 MHz, D2O) 9.57 (dd, 1H), 9.19 (s, 1H), 8.32 (dd, 1H), 7.22-7.35 (m, 5H), 4.73-4.95 (t, 2H), 3.45 (s, 3H), 3.06 (t, 2H) (CO2H proton missing)
To a solution of pyridazine-4-carboxylic acid (0.6 g) in acetonitrile (25 mL) at room temperature under a nitrogen atmosphere was added triethylamine (2.04 mL), propylphosphonic anhydride (6.15 g) and piperidine (0.52 mL). The reaction mixture was stirred at room temperature for 16 hours, then concentrated, diluted with water (50 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were concentrated and purified by chromatography on silica eluting with 45% ethyl acetate in hexanes to afford 1-piperidyl(pyridazin-4-yl)methanone as a white solid.
1H NMR (400 MHz, D2O) 9.33 (dd, 1H) 9.26 (dd, 1H) 7.71 (dd, 1H) 3.63-3.57 (m, 2H) 3.24-3.18 (m, 2H) 1.66-1.44 (m, 6H)
To a solution of 1-piperidyl(pyridazin-4-yl)methanone (300 mg) in acetonitrile (6 mL) was added methyl 3-bromopropanoate (0.324 g). The mixture was heated at 90° C. for 18 hours, then cooled and concentrated. The crude product was washed with methyl tert-butyl ether (50 mL) to afford crude methyl 3-[4-[methyl(phenyl)carbamoyl]pyridazin-1-ium-1-yl]propanoate bromide as yellow gum, which was used without further purification.
A solution of crude methyl 3-[4-[methyl(phenyl)carbamoyl]pyridazin-1-ium-1-yl]propanoate bromide (485 mg) in 2M aqueous hydrochloric acid (10 mL) was stirred at room temperature for 24 hours. The reaction mixture was concentrated and purified by preparative reverse phase HPLC (trifluoroacetic acid is present in the eluent) to afford 3-[4-(piperidine-1-carbonyl)pyridazin-1-ium-1-yl]propanoic acid trifluoroacetate.
1H NMR (400 MHz, D2O) 9.68-10.04 (m, 1H), 9.32-9.64 (m, 1H), 8.39-8.75 (m, 1H), 5.00-5.22 (m, 2H), 3.56-375 (m, 2H), 3.28-3.34 (m, 2H), 3.18-3.25 (m, 2H), 1.63-1.73 (m, 4H), 1.44-1.61 (m, 2H) (CO2H proton missing)
A mixture of 2-aminophenol (0.19 mL), pyridazine-4-carbaldehyde (250 mg), activated charcoal (194 mg) and o-xylene (10 mL) was heated at 120° C. overnight. The reaction mixture was filtered through celite, concentrated and purified by preparative reverse phase HPLC (trifluoroacetic acid is present in the eluent) to give 2-pyridazin-4-yl-1,3-benzoxazole as a beige solid.
1H NMR (400 MHz, CD3OD) 9.93 (dd, 1H), 9.45 (dd, 1H), 8.40 (dd, 1H), 7.89-7.84 (m, 1H), 7.78 (dd, 1H), 7.57-7.46 (m, 2H)
A mixture of 2-pyridazin-4-yl-1,3-benzoxazole (100 mg), 2-bromoethanesulfonic acid (131 mg) and water (2 mL) was heated at 100° C. for 20 hours. Further 2-bromoethanesulfonic acid (131 mg) was added and heating continued for a further 6 hours. The reaction mixture was concentrated and purified by preparative reverse phase HPLC (trifluoroacetic acid is present in the eluent) to give 2-[4-[(2-hydroxyphenyl)carbamoyl]pyridazin-1-ium-1-yl]ethanesulfonate as an orange solid.
1H NMR (400 MHz, DMSO-d6) 10.60 (s, 1H), 10.11 (d, 1H), 9.99-9.83 (m, 2H), 9.00 (dd, 1H), 7.65 (br d, 1H), 7.16-7.07 (m, 1H), 6.96 (d, 1H), 6.87 (t, 1H), 5.13 (br t, 2H), 3.27-3.20 (m, 2H)
To a solution of N-ethylpyridazine-4-carboxamide (0.3 g) in dry acetonitrile (6 mL) was added tert-butyl N-[(3S)-2-oxooxetan-3-yl]carbamate (0.668 g) at room temperature, under nitrogen atmosphere. On completion the reaction mixture was concentrated and purified using preparative reverse phase HPLC (trifluoroacetic acid is present in the eluent) to give crude (25)-2-(tert-butoxycarbonylamino)-3-[4-(ethylcarbamoyl)pyridazin-1-ium-1-yl]propanoic acid 2,2,2-trifluoroacetate which was used in the next step without further purification.
LCMS: retention time 0.29 min, M+339
A mixture of (2S)-2-(tert-butoxycarbonylamino)-3-[4-(ethylcarbamoyl)pyridazin-1-ium-1-yl]propanoic acid 2,2,2-trifluoroacetate (0.06 g) and 2M aqueous hydrochloric acid (4 mL) was stirred at room temperature for 24 hours. The reaction mixture was concentrated under vacuum and purified by preparative reverse phase HPLC (trifluoroacetic acid is present in the eluent) to give of [(1S)-1-carboxy-2-[4-(ethylcarbamoyl)pyridazin-1-ium-1-yl]ethyl]ammonium; 2,2,2-trifluoroacetate.
1H NMR (400 MHz, D2O) 10.00 (d, 1H), 9.80 (d, 1H), 8.90-8.93 (m, 1H), 5.49 (d, 2H), 4.64 (t, 1H), 3.46-3.52 (m, 2H), 1.25 (t, 3H). (NH and CO2H protons missing)
To a solution of N-ethylpyridazine-4-carboxamide (0.3 g) in dry acetonitrile (6 mL) was added [(1S)-3-bromo-1-methoxycarbonyl propyl]ammonium chloride (0.55 g, preparation as described in WO2019/034757) at room temperature, under nitrogen atmosphere. The reaction mixture was heated at reflux for 16 hours, concentrated and purified by preparative reverse phase HPLC (trifluoroacetic acid is present in the eluent) to give [(1S)-3-[4-(ethylcarbamoyl)pyridazin-1-ium-1-yl]-1methoxycarbonyl-propyl]ammonium 2,2,2-trifluoroacetate as a gum.
1H NMR (400 MHz, D2O) 9.92 (d, 1H), 9.74 (dd, 1H), 8.83 (dd, 1H), 5.16 (t, 2H), 4.33 (dd, 1H), 3.83 (s, 3H), 3.44 (q, 2H), 2.78-2.83 (m, 1H), 2.66-2.76 (m, 1H), 1.20 (t, 3H) (NH protons missing)
A mixture of methyl (2S)-2-amino-4-[4-(ethylcarbamoyl)pyridazin-1-ium-1-yl]butanoate 2,2,2-trifluoroacetate (0.05 g) in 2M aqueous hydrochloric acid (1 mL) was heated at 60° C. for 12 hours. The reaction mixture was concentrated to give [(1S)-1-carboxy-3-[4-(ethylcarbamoyl)pyridazin-1-ium-1-yl]propyl]ammonium dichloride as a gum.
1H NMR (400 MHz, D2O) 9.94 (d, 1H), 9.75 (d, 1H), 8.83 (dd, 1H), 5.18 (t, 2H), 4.11-4.18 (m, 1H), 3.46 (q, 2H), 2.68-2.84 (m, 2H), 1.21 (t, 3H) (NH and CO2H protons missing)
Step 1: Preparation of tert-butyl N-(3-oxopropyl)carbamate
To a solution of 3-(Boc-amino)-1-propanol (5 g) in dichloromethane (150 mL) at 0° C., under nitrogen atmosphere, was added Dess-Martin Periodinane (14.08 g). The reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction mixture was diluted with water (120 mL) and extracted with dichloromethane (3×70 mL). The combined organic layers were washed with 1M aqueous sodium thiosulfate and saturated sodium bicarbonate, dried over sodium sulfate and concentrated to give tert-butyl N-(3-oxopropyl)carbamate as a brown gum, which was used in the next step without further purification.
To a solution of tert-butyl N-(3-oxopropyl)carbamate (5 g) in ethanol (100 mL) was added hydroxylamine hydrochloride (2.82 g) and sodium carbonate (8.26 g) and the resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water (120 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with water, brine, dried over sodium sulfate and concentrated to give tert-butyl N-(3-hydroxyiminopropyl)carbamate as a brown solid, which was used in the next step without further purification.
To a solution of tert-butyl N-(3-hydroxyiminopropyl)carbamate (4.5 g) in N,N-dimethylformamide (45 ml), at room temperature, was added N-chlorosuccinimide (3.95 g) portion wise. After stirring for 2 hours potassium carbonate (4 g) was added and the reaction mixture was cooled to −40° C. The mixture was purged with isobutylene gas (˜14 g) for ˜30 minutes at −40° C. and then stirred at same temperature for 4 hours. The reaction was slowly warmed to room temperature and stirred for 18 hours. The reaction was quenched with ice water and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, concentrated and purified by silica gel column chromatography eluting with a mixture of ethyl acetate in iso-hexane to give tert-butyl N-[2-(5,5-dimethyl-4H-isoxazol-3-yl)ethyl]carbamate as off white solid.
1H NMR (400 MHz, CDCl3) 4.95 (br s, 1H), 3.40 (br d, 2H), 2.70 (s, 2H), 2.46 (t, 2H), 1.42 (s, 9H), 1.37 (s, 6H)
To a solution of tert-butyl N-[2-(5,5-dimethyl-4H-isoxazol-3-yl)ethyl]carbamate (1 g) in dichloromethane (20 mL), at 0° C., was added 2,2,2-trifluoroacetic acid (2.87 mL). The reaction was warmed to room temperature and stirred for 18 hours. The reaction mass was concentrated and the resulting residue was washed with tert-butyl methyl ether (2×20 mL) and dried under reduced pressure to give 2-(5,5-dimethyl-4H-isoxazol-3-yl)ethylammonium 2,2,2-trifluoroacetate as an off-white solid.
1H NMR (400 MHz, DMSO-d6) 7.88 (br s, 3H), 3.00-3.09 (m, 2H), 2.76 (s, 2H), 2.57 (t, 2H), 1.29 (s, 6H)
To a solution of (2,3,4,5,6-pentafluorophenyl) pyridazine-4-carboxylate (0.5 g) in acetonitrile (10 mL) at room temperature was added 2-(5,5-dimethyl-4H-isoxazol-3-yl)ethylammonium 2,2,2-trifluoroacetate (0.48 g) and potassium carbonate (0.6 g). The reaction mass was subjected to microwave irradiation at 100° C. for 1 hour. The reaction was concentrated and purified by silica gel column chromatography eluting with a mixture of methanol in dichloromethane to afford N-[2-(5,5-dimethyl-4H-isoxazol-3-yl)ethyl]pyridazine-4-carboxamide.
1H NMR (400 MHz, CD3OD) 9.49 (dd, 1H), 9.37 (dd, 1H), 8.00 (dd, 1H), 3.67 (t, 2H), 2.88 (s, 2H), 2.65 (t, 2H), 1.35 (s, 6H) (NH proton missing)
To a solution of N-[2-(5,5-dimethyl-4H-isoxazol-3-yl)ethyl]pyridazine-4-carboxamide (0.25 g) in acetonitrile (5 mL) was added 3-bromopropanoic acid (0.32 g) and the mixture was heated at 80° C. for 18 hours. The reaction mass was cooled, concentrated and purified by preparative reverse phase HPLC (trifluoroacetic acid is present in the eluent) to give 3-[4-[2-(5,5-dimethyl-4H-isoxazol-3-yl)ethylcarbamoyl]pyridazin-1-ium-1-yl]propanoic acid 2,2,2-trifluoroacetate as an off-white solid.
1H NMR (400 MHz, D2O) 9.94 (d, 1H), 9.68 (d, 1H), 8.76 (dd, 1H), 5.15 (t, 2H), 3.67 (t, 2H), 3.26 (t, 2H), 2.93 (s, 2H), 2.67 (t, 2H), 1.32 (s, 6H) (NH and CO2H protons missing)
For compound A131 synthesis of the amine can be found in WO16071359.
1H NMR
Seeds of a variety of test species were sown in standard soil in pots. After cultivation for 14 days (post-emergence) under controlled conditions in a glasshouse (at 24/16° C., day/night; 14 hours light; 65% humidity), the plants were sprayed with an aqueous spray solution derived from the dissolution of the technical active ingredient formula (I) in a small amount of acetone and a special solvent and emulsifier mixture referred to as IF50 (11.12% Emulsogen EL360 TM+44.44% N-methylpyrrolidone+44.44% Dowanol DPM glycol ether), to create a 50 g/l solution which was then diluted to required concentration using 0.25% or 1% Empicol ESC70 (Sodium lauryl ether sulphate)+1% ammonium sulphate as diluent.
The test plants were then grown in a glasshouse under controlled conditions (at 24/16° C., day/night; 14 hours light; 65% humidity) and watered twice daily. After 13 days the test was evaluated (100=total damage to plant; 0=no damage to plant).
The results are shown in Table B (below). A value of n/a indicates that this combination of weed and test compound was not tested/assessed.
Ipomoea hederacea (IPOHE), Euphorbia heterophylla (EPHHL), Chenopodium album (CHEAL), Amaranthus palmeri (AMAPA), Lolium perenne (LOLPE), Digitaria sanguinalis (DIGSA), Eleusine indica (ELEIN), Echinochloa crus-galli (ECHCG), Setaria faberi (SETFA)
| Number | Date | Country | Kind |
|---|---|---|---|
| 201811042468 | Nov 2018 | IN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2019/080951 | 11/12/2019 | WO | 00 |
